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The cellular reorganization of the 
brain tissue during epileptogenesis 
has been widely characterized, 
however, the molecular alterations 
evoking these changes are poorly 
understood. The aim of this study 
was to characterize the gene-
expression changes that occur during 
epileptogenesis and to study the 
function of one of the genes in detail. 
Expression and activity of uPA and 
its receptor uPAR was investigated 
in the normal rat brain and during 
epileptogenesis and the role of uPA in 
neurodegeneration, neurogenesis and 
granule cell dispersion was assessed 
using uPA knockout mice.
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ABSTRACT
Temporal lobe epilepsy (TLE) is the most common form of epilepsy in adults and the epileptic process 
typically develops in three phases: the initial brain damaging insult [brain trauma, brain infection, 
status epilepticus (SE), stroke etc.], a latency period (epileptogenesis) and finally recurrent seizures 
(epilepsy). Epileptogenic insults are known to trigger neurobiological reorganization events in the 
brain such as neuronal death, neurogenesis, gliosis, granule cell dispersion (GCD), mossy fiber
sprouting (MFS), rearrangement of channels and receptors and angiogenesis. Rearrangement of the 
brain tissue develops insidiously during the latency period or epileptogenesis phase and ultimately lead 
to the occurrence of seizures. The cellular alterations have been widely studied and characterized,
however, the molecular alterations evoking these changes are poorly understood. In the first phase of 
this study, the gene-expression changes occuring during epileptogenesis and epilepsy were profiled. 
Next one of the highly upregulated genes was selected for more detailed studies to elucidate its 
expression and function during epileptogenesis. Urokinase-type plasminogen activator (uPA) was 
chosen as it is a part of the plasminogen system which has been implicated in various tissue 
reorganization events.
A rat model of TLE was used, where epileptogenesis is triggered with SE, in order to analyze the 
gene-expression changes in different phases of epileptogenesis and epilepsy using cDNA-array 
technology and RT-PCR. Next, expression of uPA as well as its receptor uPAR was studied with 
immunohistochemical methods and enzyme activity was measured with zymography. The role of uPA 
in neurodegeneration, neurogenesis, and GCD after SE was evaluated using uPA deficient mice.
The main results are: 1) In the normal rat hippocampus, the expression of uPA and uPAR is low. 2) 
After SE the expression of uPA and uPAR is increased and the most profound expression is found 1-4
d after SE. The activity of uPA becomes upregulated at 1 d and remains elevated still 14 d after SE. 3) 
After SE, uPA and uPAR are expressed in astrocytes, pyramidal neurons and blood vessels. uPAR is 
also highly expressed in hippocampal parvalbumin interneurons after SE. 4) In the mouse 
intrahippocampal kainic acid (KA) model, uPA deficiency does not affect acute neuronal death but 
promotes neurodegeneration at 20 d after SE. 5) uPA deficiency leads to a decline in hippocampal 
neurogenesis 20 d after SE in mice. 6) uPA deficiency does not affect GCD in the mouse brain after 
SE.
In summary, it was found that uPA and uPAR are induced in the rat hippocampus during 
epileptogenesis in areas that undergo several epileptogenic alterations. Further, uPA was observed to
modulate neurodegeneration and neurogenesis in the mouse model of TLE.
National Library of Medicine Classification: WL 385, WL 314, QU 475, QU 450, QU 135, QU 142 
Medical Subject headings: Epilepsy; Epilepsy, Temporal Lobe; Gene Expression; Gene Expression Profiling; Status Epilepticus;
Urokinase-Type Plasminogen Activator; Receptors, Urokinase Plasminogen Activator; Hippocampus; Astrocytes; Pyramidal 
Cells; Blood Vessels; Disease Models, Animal; Rats; Mice; Mice, Knockout; Neurons; Cell Death; Immunohistochemistry
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TIIVISTELMÄ
Ohimolohkoepilepsia on yleisin epilepsiatyyppi aikuisilla ja useimmiten sen kehittyminen voidaan 
jakaa kolmeen vaiheeseen: aivoja vaurioittava tapahtuma (esim. pään vamma, aivoleikkaus, 
aivohalvaus, aivoinfektio, status epilepticus), epilepsian kehittyminen (epileptogeneesi) ja spontaanit 
toistuvat kohtaukset (epilepsia). Aivoja vaurioittava tapahtuma johtaa neurobiologisiin muutoksiin 
joihin kuuluu mm. hermosolujen kuolema, uusien hermosolujen synty, hermotukisolujen lisääntyminen
(glioosi), aksonien ja dendriittien uudelleenjärjestäytyminen sekä uusien verisuonien synty. Näihin 
muutoksiin johtavat molekyylitason muutokset tunnetaan vielä huonosti. Tämä tutkimus on osa laajaa 
projektia jonka tavoitteena on saada lisää tietoa epilepsiaan johtavista molekyylitason muutoksista 
aivoissa. Tutkimuksen ensimmäisessä vaiheessa profiloimme epileptogeneesin ja epilepsian 
aiheuttamia muutoksia geenien ilmentymisessä. Seuraavaksi valitsimme yhden geeneistä, urokinaasi-
tyyppisen plasminogeeniaktivaattorin (uPA), tarkempiin tutkimuksiin koska uPA:n on aikaisemmin 
osoitettu osallistuvan erilaisiin kudosten uudelleenjärjestäytymisprosesseihin.
Geenien ilmentymisen muutoksia tutkittiin mallilla jossa epileptogeneesi stimuloidaan 
aiheuttamalla rotille status epilepticus (SE) amygdalan sähköisellä stimulaatiolla. Geenien 
ilmentymisen muutoksia rotan aivoissa tutkittiin cDNA geenisirutekniikalla sekä RT-PCR tekniikalla. 
uPA:n ja sen reseptorin (uPAR) ilmentymistä tutkittiin normaaleissa rotan aivoissa ja epileptogeneesin 
eri vaiheissa immunohistokemiallisilla menetelmillä. Lisäksi uPA:n entsyymi aktiivisuutta tutkittiin 
zymografialla. uPA poistogeenisten hiirien avulla tutkimme uPA:n roolia epileptogeneesin aikana 
hippokampuksessa tapahtuvissa neurobiologisissa muutoksissa (hermosolujen tuhoutuminen, 
jyvässolujen hajaantuminen, neurogeneesi).
Tärkeimmät tulokset: 1) normaalissa rotan hippokampuksessa uPA ja uPAR määrä on vähäinen. 2) 
SE jälkeen uPA ja uPAR määrä kasvaa rotan hippokampuksessa, suurin muutos tapahtuu 1-4 päivää 
SE jälkeen. uPA:n entsymaattinen aktiivisuus pysyy kohonneena 1-14 päivää SE jälkeen. 3) SE jälkeen 
uPA ja uPAR ilmentyvät hippokampuksen astrosyyteissä, pyramidaali neuroneissa ja verisuonissa. 
Lisäksi uPAR ilmentyy voimakkaasti hippokampuksen parvalbumiini interneuroneissa. 4) uPA 
poistogeenisyys ei vaikuta hippokampuksen akuuttiin solutuhoon SE jälkeen (6 päivää) mutta lisää 
solutuhon laajuutta 20 päivää SE jälkeen. 6) uPA poistogeenisillä hiirillä syntyy vähemmän uusia 
hermosoluja SE jälkeen kuin villityypin hiirillä.7) uPA puutos ei vaikuta hippokampuksen jyvässolujen 
hajaantumiseen SE jälkeen.
Tässä tutkimuksessa osoitamme sekä mRNA että proteiinitasolla että uPA ja uPAR ilmentyvät 
rotan hippokampuksen astrosyyteissä ja hermosoluissa epileptogeneesin aikana alueilla joilla tapahtuu 
huomattavia neurobiologisia muutoksia. Lisäksi osoitamme että uPA vaikuttaa epileptogeneesin aikana 
tapahtuvaan hermosolujen tuhoutumiseen sekä uusien hermosolujen syntyyn hiiren aivoissa.
Luokitus: WL 385, WL 314, QU 475, QU 450, QU 135, QU 142
Yleinen suomalainen asiasanasto (YSA): epilepsia; molekyylibiologia; geenit; entsyymit; reseptorit; hippokampus; koe-eläimet; 
rotat; hiiret
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11. INTRODUCTION
Epilepsy is one of the most common neurological diseases, affecting around 1% of the world’s 
population. Temporal lobe epilepsy (TLE) represents the most common form of acquired epilepsy and 
it usually develops in three phases: the initial brain damaging insult [head trauma, status epilepticus
(SE), stroke, brain infection etc.], then the latency phase (epileptogenesis) and finally recurrent 
epileptic seizures (epilepsy) (Mather et al., 1996). The initial insult triggers a cascade of brain 
reorganization events that include neurodegeneration, gliosis, granule cell dispersion (GCD), mossy 
fiber sprouting (MFS), neurogenesis, angiogenesis and reorganization of channels and receptors
(Pitkänen and Sutula, 2002). These cellular changes occur during the latency phase and this can last for 
years in humans, leading to changes in brain excitability and ultimately to the appearance of seizures
(Pitkänen and Sutula, 2002). Although, the cellular reorganization events are well documented and
have been widely studied, the underlying molecular alterations are still poorly understood. Profiling of 
the molecular cascades could provide help in developing new antiepileptic drugs as well as 
possibilities to modulate the development of cellular changes during epileptogenesis, and possibly to 
prevent epilepsy.
cDNA array technology provides a possibility to study the expression of thousands of genes 
simultaneously. This has also provided a tool for screening genes involved in epileptogenesis. There 
are studies demonstrating that the gene expression of several hundred genes is altered after SE, the true 
number may be thousands (Hevroni et al., 1998; Zagulska-Szymczak et al., 2001; Gorter et al., 2007). 
However, detailed studies of gene-expression changes during the progression of epileptogenesis have 
been lacking. Thus, in the first part of this study, the aim was to obtain a more detailed temporal profile 
of the gene-expression changes during different phases of epileptogenesis in the two brain areas most 
affected in TLE, hippocampus and extrahippocampal temporal lobe. Further, epileptogenesis-related 
genes were compared to genes modulated during epilepsy.
In the next phase of the study, it was decided to study the expression and function of one of the 
highly upregulated genes in detail. Urokinase-type plasminogen activator (uPA) was chosen for further 
studies as it is a part of a major proteolytic system, the plasminogen system, which is known to
participate in the reorganization of several tissues. The reorganization of a tissue requires proteolysis
of the extracellular matrix (ECM) and cell contact molecules and there is increasing evidence to point 
to a crucial role of the plasminogen system in the reorganization of nervous tissue occurring after brain 
trauma (Gingrich and Traynelis, 2000; Lo et al., 2002; Gorter et al., 2007; Siao and Tsirka, 2002) as 
well as in several brain pathologies (Alonso et al., 1996; Tucker et al., 2000, 2002;Gveric et al., 2001; 
Teesalu et al., 2001; Iyer et al., 2010). uPA cleaves plasminogen to active plasmin, and this protein
2
also functions as one of the activators of uPA, forming an efficient proteolytic cycle. Plasmin and uPA 
can degrade various proteins of the ECM and activate matrix metalloproteinases as well as growth 
factors (Irigoyen et al., 1999). uPA binding to a specific receptor, uPAR, regulates uPA activity and 
localizes it to the cell surface. uPAR can also initiate intracellular signaling events known to regulate 
cell-migration, invasion, proliferation and differentiation (Blasi and Carmeliet, 2002). uPA and uPAR 
have been shown to be expressed during nervous tissue development and to have a role in the 
reorganization events in various tissues, suggesting that these molecules could also contribute to the 
reorganization of brain tissue during epileptogenesis. 
The present study focuses on the expression and activity of uPA and its receptor uPAR in normal, 
epileptogenic and epileptic rat hippocampus. The effect of uPA deficiency was examined in the
common neurobiological changes that occur in the hippocampus during epileptogenesis, including
neurodegeneration, neurogenesis and GCD.
32. REVIEW OF THE LITERATURE
2.1 Epilepsy
2.1.1 Definition of epilepsy
In simple terms epilepsy can be defined as recurrent epileptic seizures caused by abnormal and 
excessive activity in the brain. Epileptic seizure is transient and often a sudden malfunction of the 
brain that can cause alterations in consciousness, behavior, emotion, motor function, and/or sensations. 
The clinical manifestation depends on the brain structures involved. Anyone can experience one 
epileptic seizure during their lifetime for example due to stress, alcohol, drugs or lack of sleep. A 
single seizure without any enduring epileptogenic abnormality or seizures that have immediate 
precipitating factor such as alcohol withdrawal seizures are not an indication of epilepsy. Thus, usually 
seizures must be spontaneous and recurrent to be diagnosed as epilepsy. Epilepsy is a highly 
heterogeneous group of brain disorders that vary in causes, time of onset, features, and prognosis. 
According to the current definition of the International League Against Epilepsy (ILAE), epilepsy is a 
disorder of the brain that is characterized by enduring predisposition to generate epileptic seizures
and by the neurobiologic, cognitive, psychological, and social consequences of this condition. The 
definition of epilepsy requires the occurrence of at least one epileptic seizure (Fisher et al., 2005).
More than 40 individual epileptic syndromes have been described for humans (Commission on 
Classification and Terminology of ILAE, 1989). 
2.1.2 Classification of epilepsy
The international classification (ILAE, 1989) divides epileptic seizures into generalized or partial 
seizures according to the place of seizure onset. Generalized seizures result from the abnormal activity 
of both brain hemispheres at the same time (primarily generalized seizure). Thus, no particular location
for seizure onset can be found, however is currently believed to originate from the cortex. Partial or 
focal seizures arise from one distinct part of the brain. Partial seizures most commonly originate from 
the temporal lobe. The temporal lobe contains two important seizure-prone structures, the amygdala 
and the hippocampus. A seizure may start as being partial and then turn into a secondary generalized 
seizure. 
Epileptic syndromes can be divided into symptomatic, idiopathic, or cryptogenic epilepsies 
according to their etiology (ILAE, 1989). Epilepsies of known etiology are called symptomatic or 
secondary epilepsies, i.e. an underlying cause can be identified. Symptomatic epilepsies are the most 
common type in adults. Epilepsies with no known underlying cause other than a possible hereditary 
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predisposition (genetic factors) are called idiopathic. Terms such as presumed or probably 
symptomatic are used when the cause of epilepsy is not known but is presumed to be symptomatic
(previously the term “cryptogenic” has been used).
2.1.3 Definition of epileptogenesis
The term “epileptogenesis” describes the process where irreversible changes occur in the brain, making 
the brain prone to recurrent epileptic seizures. Epileptogenesis is also described as the silent period or 
latency phase as no seizures are observed during this time. The neurobiological changes that take place 
during epileptogenesis include neurodegeneration, neurogenesis, gliosis, angiogenesis, axonal and 
dendritic reorganization, rearrangement of ECM as well as channels and receptors (Jutila et al., 2002a; 
Pitkänen and Lukasiuk, 2009). These structural changes result from molecular alterations (changes in 
gene and protein expression) triggered by epileptogenic insults. Several brain damaging insults can 
trigger epileptogenesis; these include traumatic brain injury (TBI), brain surgery, stroke, SE and brain 
infections (Mathern et al., 1996; Pitkänen et al., 2007). Epileptogenesis can last for years in humans, in 
animal models of epilepsy, the latency phase is usually shorter, ranging from a few days to months.
The difference in the duration of the latency phase in humans and animal model is most likely due to 
the greater brain damage inflicted in animal models. In rats, the duration of the latency period depends 
greatly on the etiology (Pitkänen et al., 2007).
2.1.4 Temporal lobe epilepsy
Temporal lobe epilepsy (TLE) is the most common form of symptomatic epilepsy (Engel, 1996) and
the most common form of drug-refractory epilepsy (Engel, 1996; Hauser and Hesdorffer, 2001). The 
seizures typically start from temporal lobe structures including the hippocampus, amygdala, subicular 
complex entorhinal and perirhinal cortices (Engel 1996). TLE typically develops in three phases as in 
the other symptomatic epilepsies: brain-damaging insult, latency phase (epileptogenesis), recurrent 
seizures (epilepsy) (see FIG.1). Common brain damaging epileptogenic insults triggering development 
of TLE include TBI, stroke, SE and brain infection (Mathern et al., 1996; Pitkänen et al., 2007). This is 
followed by epileptogenesis during which there are no seizures but several neurobiological changes
occur, and these make the brain prone to develop seizures (Jutila et al., 2002a; Pitkänen and Lukasiuk, 
2009). The epileptogenesis or latency phase can last from months to several years in humans but 
ultimately recurrent seizures appear (epilepsy). 
The current treatment of TLE is focused on seizure prevention. Despite the wide armoyry of 
antiepileptic drugs, about 30% of patients remain pharmacoresistant (Hauser and Hesdorffer, 2001). A 
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subgroup of these patients may obtain relief from epilepsy surgery where the epileptic focus is resected 
(Jutila et al., 2002b). However, a large group of TLE patients cannot be helped with current treatments 
and they often suffer from increasing seizure frequency and a decline in their cognitive functions
(Pitkänen and Sutula, 2002).
FIGURE 1. The typical process of epileptogenesis in temporal lobe epilepsy. The initial brain 
damaging insult initiates a cascade of molecular and cellular alterations in the brain, leading ultimately 
to the occurrence of seizures i.e. epilepsy. In humans the epileptogenesis phase can last from weeks to 
years. Reorganizations of neuronal tissue continue also during epilepsy (Pitkänen and Sutula, 2002).
2.1.5 Status Epilepticus
Status epilepticus (SE) is usually defined as continuous seizure activity that lasts for more than 30 min 
or intermittent seizures over period of 30 min without full recovery of consciousness between seizures 
(Waterhouse and Delorenzo, 2001). SE is a medical emergency associated with high mortality. 
Therefore, in clinical practice, a generalized tonic-clonic seizure lasting for more than 5-10 minutes 
would usually be considered as SE and treated as such. Different studies have reported a minimal 
incidence of SE of approximately 10-20/100000 humans (reviewed in Rosenow et al., 2007). The 
major causes of SE in adults are acute and remote cerebrovascular accidents, hypoxia, metabolic 
causes, and inadequate antiepileptic drug levels (DeLorenzo et al., 1996; Knake et al., 2001). In animal 
models, SE is characterized by severe limbic seizures that cause several neuropathological phenomena 
including opening of the blood-brain barrier, brain edema, bleeding into the brain, and activation of 
microglia and astrocytes, followed by, neurodegeneration in the hippocampus, amygdala, entorhinal 
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cortex, and other brain areas (Sperk et al., 1983, 2009). The risk of recurrent seizures after SE in 
humans is 37% within 1 year and 56% within 3 years (Hauser et al., 1990ab). According to 
epidemiological studies, epilepsy will develop in up to 42% of patients with SE (Hesdorffer et al., 
1998). In animal models of SE, 50-100% of animals develop epilepsy (Meierkord et al., 2007). As SE 
can be evoked by brain damage and it can cause brain damage itself, differentiating between these two
conditions in the human brain can be difficult. According to animal models, one of the most commonly 
described pathologies that occurs after SE is an extensive loss of neurons within the hilar area of the 
dentate gyrus of the hippocampus as well as a loss of selective populations of interneurons in areas of
CA1 and CA3 and in the hilus (reviewed in Coulter and DeLorenzo, 1999).
2.2 Neuropathology of temporal lobe epilepsy
2.2.1 Hippocampal sclerosis
Ammon's horn sclerosis (AHS) or hippocampal sclerosis is a term used to describe a specific pattern of 
neuronal loss, granule cell dispersion and reactive gliosis found in the hippocampus of 60-90% of TLE 
patients who have been subjected to epilepsy surgery (Blümcke et al., 2002; Thom et al., 2002; 
Majores et al., 2007). Histopathologically, AHS is characterized by segmental neuronal loss in CA1, 
CA3 and hilus, whereas CA2 pyramidal cells and DG granule neurons are more resistant (Blümcke et 
al., 2002; Sloviter et al., 2004; Thom et al., 2005). In conjunction with the hippocampal formation, the 
entorhinal cortex and amygdala complex are subjected to cellular damage in many TLE patients 
(Pitkänen et al., 1998; Yilmazer-Hanke al., 2000; Dawodu and Thom, 2005). There has been a
vigorous debate about whether AHS is the cause or a consequence of TLE. Recurrent seizures and a
long duration of epilepsy are associated with severe hippocampal sclerosis (Davies et al., 1996). 
Further, resection of the sclerotic hippocampus can be beneficial in many of the operated TLE patients 
(de Lanerolle et al., 2003; Dupont et al., 2006). However, a subgroup of operated TLE patients does
not display AHS (Blümcke et al., 2002; Thom et al., 2002). 
2.2.2 Neurodegeneration
Neuronal cell death is the most apparent neuropathological finding in TLE. In the hippocampus of 
most TLE patients, there is significant neuronal loss of CA1-CA3 pyramidal neurons and hilar cells. 
Hilar cells seem to be the most vulnerable cells in the hippocampus and the extent of hilar cell loss has
been correlated with hippocampal hyperexcitability (Sloviter, 1991; Lowenstein et al., 1992; 
Scharfman and Schwartzkroin, 1990). Further, hippocampal interneurons show different 
7
susceptibilities to neurodegeneration (Mathern et al., 1995; Sloviter et al., 2003). In addition to 
hippocampal damage, neurodegeneration has been described also in the amygdala and the surrounding 
entorhinal, perirhinal, and parahippocampal cortices, as well as in many extratemporal areas, including 
the thalamus and cerebellum of TLE patients (Jutila et al., 2002a). Continuous seizure activity has been 
shown to kill neurons. After SE, most of the neurodegeneration occurs within a few days after the 
insult, however neurodegeneration may continue for up to 2 months after SE (Pitkänen and Sutula, 
2002). Several attempts have been made to block epileptogenesis in animal models with
neuroprotective agents. Though substantial neuroprotection has been achieved in these studies, the 
development of epilepsy could not be prevented (Ebert et al., 2002; Brandt et al., 2003; Narkilahti et 
al., 2003).
2.2.3 Granule cell dispersion
One frequent pathological finding in TLE, hippocampal sclerosis, is often associated with granule cell 
dispersion (GCD) (Houser, 1990a; Mathern et al., 1997; Blümcke et al., 2002). GCD means 
enlargement of the granule cell layer due to the malpositioning of the granule neurons in the molecular 
layer and the disappearance of any clear border between the GCL and the molecular layer (Houser, 
1990). Sometimes GCD develops as a bilaminar organization of the granule cell layer (Houser, 1990).
According to the study of Thom et al. (2002), severe GCD is observed in approximately 40% of TLE 
specimens, a bilayer pattern of the granule cell layer in 10% of cases and discrete clusters or groups of 
granule cells in the molecular layer in a further 34% of cases. Several studies have depicted a
correlation between severity of GCD with the severity of neuronal loss in the hippocampus (Houser et 
al., 1990, 1992; El Bahh et al., 1999; Thom et al., 2002).
In contrast to humans, GCD is not commonly observed in animal models of TLE. One of the rare 
models showing prominent GCD is the intrahippocampal KA model used in mice. In this model, GCD 
develops in mice 15 days after intrahippocampal KA injection, reaching its maximal level by 30 days 
after injection (Bouilleret et al., 1999). Mello et al. (1992) have reported widening of the GCL from 9 
to 100 days following pilocarpine-induced SE in rats. In addition, the Na+ -K+-ATPase blocker, 
ouabain, induces a rapid dispersion of the granule cells when injected into the dentate gyrus of rats 
(Omar et al., 2000). Interestingly, in mice, GCD can also be caused developmentally by depletion of 
p35 or reelin genes (Rakic and Caviness, 1995; Wenzel et al., 2001; Heinrich et al., 2006).
It is not certain how GCD develops in TLE patients. Animal models of epilepsy have indicated that 
GCD is a consequence of enhanced neurogenesis in the subgranular zone of the dentate gyrus followed 
by an aberrant migration of the newborn dentate granule cells (Parent et al., 1997, 2006; Jessberger et 
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al., 2005; Gong et al., 2007). In contrast, recent studies have indicated that dispersion is not caused by 
increased dentate neurogenesis but rather is due to a displacement of the adult mature granule cells 
(Nitta et al., 2008; Heinrich et al., 2006). In addition, no correlation between GCD and neurogenesis 
has been found in specimens from TLE patients (Fahrner et al., 2007). Current evidence indicates that 
GCD is linked to the extracellular matrix protein, reelin. The reelin deficient reeler mouse exhibits 
altered granule cell migration similar to TLE patients (Rakic and Caviness, 1995; D'Arcangelo et al., 
1995; Frotscher et al., 2003). Further, GCD strongly correlates with a decrease in reelin expression in 
hippocampal samples both in animal models and human TLE samples (Heinrich et al., 2006; Haas et 
al., 2002, Frotscher et al., 2003) and GCD can be induced in mice with reelin-neutralizing antibody 
(Heinrich et al., 2006). The effect of reelin on neuronal migration seems to be mediated through a
dense radial glia scaffold (Lurton et al., 1998; Frotscher et al., 2003).
2.2.4 Mossy fiber sprouting
The best-characterized example of the plastic changes that occur during epileptogenesis is the 
sprouting of granule cell axons (mossy fibers) due to the loss of target neurons. Ramón y Cajal (1928) 
was the first to demostrate intracortical axonal sprouting of injured neocortical neurons and proposed 
that this sprouting might increase activity within cortical circuits. Normally mossy fibers innervate 
hilar cells and the apical dendrites of CA3 pyramidal cells. In experimental and human TLE samples, it 
has been shown that mossy fibers sprout and innervate granule cell dendrites in the inner molecular 
layer of the DG and the basal dendrites of the CA3 pyramidal cells of hippocampus proper (Tauck and 
Nadler 1985; Sutula et al., 1989; Houser et al., 1990b; Represa et al. 1990; Nissinen et al., 2000,
Pitkänen et al., 2000). Sprouting occurs also in the CA1 pyramidal cell axons in the rat hippocampus 
(Cavazos et al., 2004), as well as in the human entorhinal cortex (Mikkonen et al., 1998). Mossy fiber 
sprouting develops in rats after only a few brief seizures, progresses with repeated seizures, and 
becomes permanent (Cavazos et al., 1991). According to Nissinen et al (2001), after SE, sprouting 
occurs before any appearance of spontaneous seizures and all epileptic rats have sprouting but its 
presence is not necessarily associated with seizures. The density of mossy fiber sprouting is not 
associated with the total number of lifetime seizures or the seizure frequency in experimental models 
or in human TLE (Mello et al., 1992; Buckmaster and Dudek 1997; Pitkänen et al., 2000; Nissinen et
al., 2001). It has been shown in experimental models that many epileptogenic insults (e.g. SE, TBI, and 
stroke) trigger mossy fiber sprouting (reviewed by Pitkänen et al., 2007), but the role of mossy fiber
sprouting in epileptogenesis and epilepsy is still unclear. The sprouted mossy fibers form recurrent 
excitatory connections, and are thus believed to contribute to recurrent excitation and potentially to the 
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enhanced susceptibility to seizures (Lynch and Sutula, 2000; Sutula and Dudek, 2007). However, the 
role of mossy fibers in seizure generation has been challenged by Harvey and Sloviter (2005) who 
reported that granule cells became progressively less excitable, rather than hyperexcitable, as mossy 
fiber sprouting progressed and they did not initiate spontaneous behavioral seizures. 
2.2.5 Gliosis
The proliferation of glial cells e.g. gliosis, is a prominent feature of the epileptic hippocampus but this 
has not as widely studied as the other features of TLE. The major glial cell types are astrocytes, 
microglia, and oligodendrocytes. Astrocytes constitute 20-50% of the volume in most brain areas and
form a large interconnected web through gap junctions (Bruzzone and Giaume, 1999; Dermietzel et al., 
2000). During development, radial glia and astrocytes facilitate or guide neuronal migration (Powell et 
al., 1997). In the adult brain, astrocytes are considered as the support cells of the brain, involved in a 
wide variety of functions such as production of ECM molecules, growth factors and proteases, 
regulation of brain homeostasis and nutrient supply to neurons (Sofroniew and Winters, 2009; Heneka 
et al., 2010). Astrocytes are also an important part of the BBB and they can control cerebral blood 
flow, by releasing vasoactive substances (Heneka et al., 2010). In the hippocampus, many finely 
branching processes from a single astrocyte are estimated to make contact with several hundred 
dendrites from multiple neurons and to envelope 100000 or more synapses (Sofroniew and Winters, 
2009). There is increasing evidence supporting a role for astrocytes in CNS signal transmission. It is 
well known that astrocytes remove/take up neurotransmitters such as glutamate released by neurons
and recycle them back to the neurons (Anderson and Swanson, 2000). However, astrocytes can also 
release several neurotransmitters upon stimulation and in this way modulate synaptic transmission 
(Parpura et al., 1994; Nedergaard 1994; Volterra and Steinhäuser, 2004; Wetherington et al., 2008). 
Seizures have been shown to cause an increase in the numbers of astrocytic cells as well as changes in 
astrocytic populations and astrocytic function (Crespel et al., 2002; Binder and Steinhäuser 2006; Jabs 
et al., 2008). There are recent studies demonstrating that stimulation of astrocytes can induce neuronal 
synchronization, pointing to a role in seizure generation and spread (Tian et al., 2005; Wetherington et 
al., 2008). 
Microglia constitute about 5-20% of the total cells in mouse brain but the number of microglia can 
vary greatly between species. Microglial cells are considered as the immunocells of the brain as they 
derive from monocytes and they become activated in response to various brain insults and pathologies
(Hailer, 2008). This activation is called microgliosis and it can manifest itself as cell proliferation, 
migration, or secretion of various compounds (cytokines, proteases, free radicals, growth factors) into 
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the extracellular space as well as the clearance of cellular depris and infectious agents similarly to the 
phagocytic macrophages (Hailer, 2008; Heneka et al., 2010). Ongoing microgliosis is a common 
finding in the sclerotic hippocampus of TLE patients (Beach et al., 1995). Animal models have shown
that seizures induce widespread microglial activation accompanied by neuronal injury (Taniwaki et al., 
1996; Rizzi et al., 2003, Borges et al., 2003). Whether microglial activation is beneficial or detrimental 
to the damaged brain is still a topic under dispute. Many of the molecules secreted by activated 
microglia are damaging to neurons however microglia also secrete factors such as transforming growth 
factor beta (TGF-, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and nerve 
growth factor (NGF), that can promote neuronal survival (Hailer, 2008). Further, microglia can take up
glutamate and this has been shown to reduce glutamate-induced neuronal death in vitro (Rimaniol et 
al., 2000). On the other hand, immunosuppression that reduces microgliosis seems to be beneficial 
during the recovery after CNS trauma or ischemia (reviewed by Hailer, 2008). Mirrione et al. (2010) 
demonstrated that ablation of microglia protected neurons from KA-induced neuronal death in mice, 
however the absence of activated (preconditioned) hippocampal microglia significantly reduced the
pilocarpine-induced seizure threshold. Thus, microgliosis may be both protective and detrimental with 
the overall outcome, depending on several factors. 
2.2.6 Neurogenesis
Contrary to an old belief that generation of new neurons i.e. neurogenesis, occurs only during 
development, neurogenesis is an ongoing process in adult mammalian brain. Altman and Das (1965) 
were the first to show that new neurons could be formed in the adult rat hippocampus. Neurogenesis in 
adult human brain was demonstrated by Eriksson et al., 1998. Subsequently, adult neurogenesis has 
been found in many mammalian species (Gould and Gross, 2002; Kornack and Rakic, 1999). It is 
generally accepted that neurogenesis occurs in two regions of the brain, at the subgranular zone of the 
dentate gyrus of the hippocampus and the subventricular zone of the anterior lateral ventricles, but also 
some other areas have been indicated (Gould and Gross, 2002). According to Kempermann et al. 
(1997a) the adult mouse produces at least 1 neuron/2000 existing granule cells per day but there are 
also strain differences in this property. The total granule cell number increases until midlife of a mouse 
(6 months) and then reaches a plateau (Kempermann et al., 1998). The rate of proliferation and the 
ratio of cells differentiating into neurons decrease with age (Kempermann et al., 1998). It has been
shown that there are several stimuli which can increase neurogenesis in mice e.g. exercise, enriched 
environment, adrenal steroids, glutamatergic neurotransmission, and naturally occurring cell death 
(Kempermann et al., 1997b; Brown wt al., 2003; Gage et al., 1998).
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Electroconvulsive shock (Scott et al., 2000) or even a single after-discharge induced by 
hippocampal stimulation increases the number of newly generated granule cells 2 weeks later 
(Bengzon et al., 1997). Dentate granule cell neurogenesis is increased also after various epileptogenic 
insults. KA induced SE (Gray and Sundstrom, 1998; Scharfman et al., 2000; Jessberger et al., 2005), 
pilocarpine-induced SE (Parent et al., 1997) and kindling (Parent et al., 1998; Scott et al., 1998) have 
been claimed to induce neurogenesis. However, in rats, the initially increased level of neurogenesis 
returns to the baseline 2 weeks after SE and neurogenesis is actually reduced 5 months after SE 
(Hattiangady et al., 2004; Heinrich et al., 2006). Early-postnatal seizures have been shown to reduce 
neurogenesis in both rats (McCabe et al., 2001) and human patients (Mathern et al., 2002). 
After an epileptogenic insult, the newly born cells could in principle be a beneficial compensatory 
reaction to the loss of neurons in the hippocampus but recent evidence has indicated that this process 
may have pro-epileptogenic effects. After SE, some of the new granule cells migrate incorrectly to the 
hilus or inner molecular layer (instead of GCL; Parent et al.,1997), where they become functionally 
integrated into the surrounding brain tissue and the aberrant connectivity promotes synchronous
discharges with the surviving CA3 pyramidal cells (Scharfman et al., 2000; Scharfman, 2004). These
incorrectly migrated neurons often have also structural abnormalities compared to normal granule cells 
(Scharfman et al., 2000). Blocking neurogenesis after seizure induction is known to attenuate the 
subsequent development of spontaneous recurrent seizures (Jung et al., 2004). Further, inhibition of 
aberrant neurogenesis can protect rats from the seizure-induced cognitive impairment in a 
hippocampus-dependent learning task (Jessberger et al., 2007).
2.2.7 Angiogenesis
Angiogenesis, i.e. endothelial cell proliferation with a subsequent increase in vascularization, is a 
crucial process during development and wound healing. A mature vascular network is complete in rats 
around postnatal day 20 (Carmeliet, 2005) and at full term in humans (Ballabh al., 2005). In the adult 
brain, endothelial cells are normally quiescent and rarely divide (Pepper et al., 2001). Angiogenesis in 
the adult brain is triggered by hypoxia (Patt et al., 1997; LaManna et al., 2004). An increase in 
capillary density in the brain has been also observed after sensory and motor training (Black et al., 
1991; Isaacs et al., 1992; Swain et al 2003).  Electroconvulsive seizures in adult rats can also induce a
profound increase in hippocampal endothelial cell proliferation (Hellsten et al., 2004) and angiogenesis 
(Hellsten et al., 2005). 
In the early 1900s, vascular dysfunction was proposed to be a causal factor for TLE or hippocampal 
sclerosis (Bratz, 1899; Spielmeyer, 1927) but this hypothesis was rejected when increased local blood 
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flow during seizures was demonstrated (Gibbs, 1934). There are recent findings to suggest that 
angiogenesis is one of the epileptogenic cellular changes occurring in the brain. One prominent 
angiogenic factor, vascular endothelial growth factor (VEGF) has been shown to be upregulated in the 
hippocampus after pilocarpine induced seizures and after experimental cerebral ischemia (Croll et al., 
2004; Nicoletti et al., 2008; Rigau et al., 2007). Endothelial cell proliferation and angiogenesis has 
been claimed to occur in animal models of TBI and stroke (Tang et al., 2007; Morgan et al., 2007), 
both leading to epilepsy in a subpopulation of animals (Pitkänen et al., 2007). Recently, Rigau et al. 
(2007) demonstrated an increase in the vessel density in the hippocampal samples of TLE patients as 
well as in the rat hippocampus after pilocarpine induced SE (4-28 d). By using unbiased stereology, 
Ndode-Ekane et al. (2010) have reported that the total blood vessel length decreases acutely after 
pilocarpine induced SE in rats but returns to the control level or even greater 2 weeks after SE and this 
is associated with increased endothelial cell proliferation. The density of the vascular network in the 
hippocampus of TLE patients does not seem to be connected with the etiology, on the degree of 
neuronal loss nor duration of epilepsy but correlates with the frequency of seizures (Rigau et al., 2007). 
Further, no correlation was found between angiogenesis and neurodegeneration nor neurogenesis 2-14 
days after pilocarpine induced SE in rats (Ndode-Ekane et al., 2010). Thus, both epileptogenic insults 
as well as seizures seem to induce angiogenesis but the role of angiogenesis in epileptogenesis and 
seizure induction needs further clarification. One hypothesis is that damage to existing vessels and 
leakiness of new vessels leads in extravasation of plasma proteins which contributes to epileptogenesis 
and ictogenesis (Seiffert et al., 2004; van Vliet et al., 2007).
2.2.8 Gene expression changes
The cellular changes that occur during epileptogenesis and epilepsy have been relatively well 
documented as reviewed above. However, the molecular alterations, underlying the reorganization of
neuronal tissue, are still poorly known. Characterization of the molecular cascades may help in 
developing new treatments for epilepsy. The development of cDNA microarray technology has 
provided an opportunity to study gene expression of hundreds or thousands of genes simultaneously. 
The use of human material in gene expression studies encounters several problems such as obtaining 
appropriate control material, possible effects of medication on gene-expression, variations in tissue 
damage and the lack of samples from the epileptogenesis phase. Thus, most studies have concentrated 
on animal models of TLE.
According to the current data, SE and other epileptogenic insults alter the expression of hundreds 
or even thousands of genes (Nedivi et al., 1993; Hevroni et al., 1998; Zagulska-Szymczak et al., 2001, 
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Tang et al., 2002; Gorter et al., 2006). It is unlikely that the change in one gene causes epilepsy alone, 
thus the identification of critical molecular cascades and functional groups of genes is important. 
Microarray experiments relevant for TLE indicate that a large numbers of functional groups of genes 
are affected during epileptogenesis including signal transduction, transcription regulation, protein 
synthesis and degradation, basic metabolism, and structural proteins (Lukasiuk and Pitkänen, 2004). 
Despite similar functional classes of genes affected by SE, epileptogenesis, and epilepsy there seems to 
be very little overlap between affected genes from different studies (reviewed by Lukasiuk and 
Pitkänen, 2004). This is probably due to the different animal models and animal strains, timepoints, 
brain areas studied, selection of gene probes and methods of analysis used in gene-expression studies 
(Lukasiuk and Pitkänen, 2004; Crino and Becker, 2006). Thus, comparison of data between studies is 
difficult.
Different brain insults can cause epilepsy and some experiments have addressed the question of
whether similar molecular cascades can be found. Tang et al. (2002) reported that all the genes induced 
in the rat cortex by SE (KA model) were also induced by ischemia, hemorrhage or hypoglycemia. On 
the other hand, about half of the genes found to be affected were unique for each model when 
ischemia, hemorrhage, and hypoglycemia induced gene-expression changes were compared (Tang et 
al., 2002). The brain area studied also affects the gene findings as shown by Rall et al. (2003); TBI 
alters the mRNA levels of 241 genes in the hippocampus and 341 genes in the frontal cortex at 24 h 
following injury. From these genes, 55 were similarly affected in both brain areas. After SE, the 
number of similarly regulated genes in different brain areas is high acutely after SE but gene-
expression changes became unique for each area during epileptogenesis (Gorter et al., 2006). Since
epileptogenesis is a cascade of events, the time-point chosen for studies may affect the results. The
recent study of Okamoto et al. (2010) indicated that 128 genes were similarly regulated in the rat 
hippocampus acutely after SE, during epileptogenesis and epilepsy. 
One important question is how well gene expression changes discovered in animal models can be 
extrapolated to the human epileptogenesis and epilepsy? In the study of Becker et al. (2003), 18 genes 
were found to be similarly regulated in epileptic rats and in human TLE samples. Only 7 genes were 
similarly regulated between 14 d epileptogenesis group and TLE patients and none at 3 days after SE. 
This is evidence that animal models can model, at least to some extent, the gene-expression changes 
that occur in the human brain.
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TABLE 1. Review list of epilepsy related gene-expression studies
Abbreviations: CA1, CA1 subfield of hippocampus; CA3, CA3 subfield of hippocampus; CB, cerebellum; DG, 
dentate gyrus; EC, enthorinal cortex; hsf, high seizure frequency; KA, kainic acid lws, low seizure frequency;
PTZ, pentylenetetrazol; SE, status epilepticus.
2.3 Animal models of temporal lobe epilepsy
The development of animal models has been crucial for investigating the development of epilepsy as 
well as developing and testing of antiepileptic drugs. A wide variety of seizure models are currently 
MODEL BRAIN AREA ALTERED GENES FOUND REFERENCE
KA induced SE in rat DG 362	
 Hevroni et al. (1998)
PTZ induced seizures
in mice
cortex, hippocampus, 
amygdala, EC, 
midbrain, and CB
49 in C57BL/6 (1 h after PTZ)
12 in 129SvEv (1 h after PTZ)
24 differently expressed genes 
between mouse strains
Sandberg et al. (2000)
electrical stimulation 
(angular bundle) 
induced SE in rat 
hippocampus 57	 Hendriksen et al. (2001)
KA induced SE in rat parietal cortex 187 	 Tang et al. (2002)
KA induced SE in rat DG 129 	 Elliott et al. (2003)
pilocarpine-induced 
SE in rat
CA1
DG
700 	
400	
51	
52	
400	
50	
52	
37	 lsf )
Becker et al. (2003)
electrical stimulation 
(angular bundle) 
induced SE in rat 
CA3
EC
CB
1050	
775
	 !
609
"	-4 mo after SE)
1241#"	
1107	 !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available, however spontaneous seizures occur only in a fraction of these models (reviewed by Fisher, 
1989; Löscher, 2002). These include systemic and intracerebral KA models, systemic injection of 
pilocarpine, electrical stimulation of hippocampus (or connected structures) or amygdala. In all of 
these models the animals experience SE as the precipitating injury and seizures appear after a latency 
period. Thus these models mimic the three levels of the epileptogenic process in human TLE and the 
histopathological findings also resemble those observed in human TLE. However, animal models often 
model only certain aspects of human TLE.
2.3.1 Amygdala stimulation model
SE can be triggered by electrical stimulation of several brain structures. Mohapel et al. (1996) 
demonstrated that the basolateral amygdala is a very sensitive structure for SE initiation. Further, the 
amygdala is often the place of seizure origin or is rapidly recruited into seizure activity in drug 
refractory TLE patients (reviewed in Aroniadou-Anderjaska et al., 2008). The amygdala stimulation 
model is specifically designed to model human TLE. In this model, the development of epilepsy is 
triggered with SE that has been initiated with unilateral 20-30 min electrical stimulation of the lateral 
nucleus of the amygdala. This induces self-sustained SE in 87% of rats that lasts for 6-20 h (Nissinen 
et al., 2000). The most severe damage, caused by SE, occurs bilaterally in the amygdala and 
surrounding cortex. Hippocampal damage is observed in 67% of the epileptic rats in Nissl stained 
sections and is characterized by cell loss in the hilus, CA1 and CA3 (Nissinen et al., 2000). In this 
model, the first spontaneous seizures occur approximately one month after SE and 87% of animals 
developed epilepsy within 6 months after SE (Nissinen et al., 2000). All rats have been shown to 
develop mossy fiber sprouting 6 months after SE (Nissinen et al., 2000). One major benefit of this 
model is that it is free of chemical substances and the latency period is longer than after administration 
of chemoconvulsants.
2.3.2 Pilocarpine model
In the pilocarpine model, SE is triggered by injecting (systemically or intracerebrally) animals with a 
non-selective muscarinic receptor agonist, pilocarpine hydrochloride. This model can be used in both
rats and mice. The ability of pilocarpine to induce SE depends on activation of the M1 muscarinic 
receptor subtype, which leads to an imbalance between excitatory and inhibitory transmission (Clifford 
et al., 1987; Hamilton et al., 1997; Priel and Albuquerque, 2002). However, once seizures have been
initiated, the maintenance of seizure activity is dependent on NMDA receptor activation (Nagao et al., 
1996; Smolders et al., 1997). After pilocarpine administration to mice or rats, the EEG alterations first 
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appear in the hippocampus and then spread to cortical areas (Turski et al., 1984; Cavalheiro et al., 
1996). The SE triggered by pilocarpine causes widespread damage to amygdala, thalamus, olfactory 
cortex, hippocampus, neocortex, and substantia nigra (Truski et al., 1984; Cavalheiro et al., 1991, 
1996; Borges et al., 2003). According to Cavalheiro et al. (1991, 1996), the latency phase or 
epileptogenesis lasts for approximately 2 weeks in rats and mice. However, according to continuous 
video-EEG studies, the latency period is only around 4-7 days in rats (Goffin et al., 2007). Similarly to 
findings in human TLE patients, pilocarpine-induced SE can evoke hippocampal cell loss, dentate 
granule cell dispersion, and supra- and intragranular mossy fiber sprouting (Mello et al., 1993; 
Cavalheiro et al., 1991, 1996).
2.3.3 Intrahippocampal kainic acid model
Kainic acid (KA or kainate) is naturally found in a seaweed, Diginea simplex, and it is a structural 
analogue of glutamic acid (glutamate) and an agonist of ionotropic, non-NMDA glutamate AMPA and 
kainate receptors. However, KA binds to kainate receptors 10 times more efficiently than to AMPA 
receptors (Swanson and Sakai et al., 2009). The neurotoxicity of KA was first demonstrated by Olney 
et al. (1974). Since then, KA has been widely used to induce seizures and epilepsy in rats and mice. 
KA can be administered systemically or intracerebrally. The neuropathological findings caused by SE 
induced with systemically administered KA are similar to those found with pilocarpine but KA 
produces less severe lesions in the neocortex and more severe lesions in the hippocampus (reviewed by 
Sharma et al., 2007). It is now established that different mouse strains have different susceptibilities to 
KA-induced neuronal damage when KA is administered systemically (Ferraro et al., 1995; 
Schauwecker, 2002; McKhann et al., 2003; McLin et al., 2006). The C57BL6 strain is especially 
resistant, thus systemic KA application cannot be used in these mice. However, unilateral injection of 
KA into the dorsal hippocampus of these mice induces a pattern of cell loss and a synaptic 
reorganization reminiscent of the alterations observed in human TLE with HS (Bouilleret et al., 1999). 
In addition, massive granule cell dispersion constitutes a unique feature of this model (Bouilleret et al., 
1999) that is not usually observed in other models of TLE. 
 Intrahippocampal KA-injection causes massive degeneration of neurons in CA1, CA3c and hilus 
that progresses over time; after one month neurons in these areas have almost completely disappeared 
from the injected side of the hippocampus (Bouilleret et al., 1999). Granule cells show an increase in 
their body size and extraneuronal space, which doubles during the first 2 weeks after KA and then 
progressively increases for several months (Suzuki et al., 1995). The cellular alterations include also 
sprouting of mossy fiber terminals in the supragranular layer of the dentate gyrus and in the 
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infrapyramidal blade of CA3 (Suzuki et al., 1995; Bouilleret et al., 2000, 1999). Further, astrogliosis is 
prominent in the injected hippocampus (Bouilleret et al., 1999). The latency phase/epileptogenesis
lasts approximately 2 weeks in this model (Riban et al., 2002). However, a non-continuous EEG-
recording scheme was used and it is most likely some seizures were missed. Our observations indicate 
that the epileptogenesis in shorter (few days) in this model (unpublished). Interestingly, this animal 
model exhibits similarities with drug refractory TLE. The seizures observed in mice are resistant to 
phenytoin, valproate, or carbamazepine and also diazepam becomes ineffective when used chronically 
(Riban et al., 2002).
2.4 The plasminogen system
The plasminogen system is a part of the fibrinolytic system and for a long time fibrinolysis was the 
only known function for the components of this system. However, it is now evident that the 
plasminogen system has a role in a wide variety of events requiring extracellular proteolysis in blood 
and tissues, such as cell migration and invasion, inflammation, angiogenesis, tissue repair and 
remodeling and embryonic development (Irigoyen et al., 1999; Andreasen et al., 2000; Blasi and 
Carmeliet, 2002). There is intense expression of most of the plasminogen activation system 
components detected during nervous system development, and expression is linked to cell movement 
and growth and remodeling of axons and dendrites (Sumi et al., 1992; Pitmann and DiBenedetto, 1995; 
Muir et al., 1998). In the adult nervous system, there is evidence pointing to a role in plastic events 
such as memory formation, neuronal death and reorganization of neuronal tissue after damage (Meiri 
et al., 1994; Tsirka et al., 1997ab; Chen and Strickland, 1997; Madani et al., 1999; Wu et al., 2000).
The key components of the plasminogen system contain plasminogen/plasmin, its activators and 
group of inhibitors and receptors (see Fig. 2). Plasmin is the active form of plasminogen. Plasminogen 
can be turned into plasmin by plasminogen activators. Two forms of plasminogen activators have been 
identified in eukaryotes, the tissue-type plasminogen activator (tPA) and the urokinase-type 
plasminogen activator (uPA). Plasminogen activators are activated by plasmin, resulting a cycle of 
activation. Plasminogen activators are inactivated by plasminogen activator inhibitors (PAIs) that 
include primarily PAI-1 and PAI-2 but also protease nexin 1 (PN-1) and protein C inactivator (PCI or 
PAI-3). The plasminogen system also contains cell surface receptors that facilitate activation reactions, 
regulate enzyme activity or initiate intracellular signaling. The best-characterized receptor of this 
system is the urokinase-type plasminogen activator receptor (uPAR; Blasi and Carmeliet, 2002).
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FIGURE 2. Simplified picture presenting the plasminogen system function and interconnection 
between molecules. Dashed lines represent inhibition. Abbreviations: ECM, extracellular matrix; 
MMP, matrix metalloproteinase, PAI, plasminogen activator inhibitor; PN-1, protease nexin-1; tPA, 
tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type 
plasminogen activator receptor. 
2.4.1 Plasminogen and plasmin
Human plasminogen is a 92-kDa proenzyme that is expressed mainly in the liver (Raum et al., 1980), 
found in plasma in high concentration but is also present in most body fluids and tissues (Zhang et al.,
2002). The human plasminogen cDNA of 2.7 kb encodes a protein consisting of 791 amino acid 
residues containing an N-terminal part with five homologous kringle domains (disulfide bonded triple 
loop structures) and the C-terminal catalytic domain that acts as an inactive proenzyme (Petersen et al., 
1990). Plasminogen is converted into active plasmin by a single proteolytic cleavage of the peptide 
bond (Arg-560 and Val-561) that turns the structure into a two-chain form (Irigoyen et al., 1999). The 
cleavage/activation is catalyzed by plasminogen activators (tPA and uPA) and certain bacterial 
proteins such as streptokinase (McCoy et al., 1991) and staphylokinase (Rijken et al., 1995) and also 
by proteolytic enzymes such as cathepsin or elastase (Machovich and Owen, 1989). The C-terminal -
chain of active plasmin contains a typical serine proteinase domain (i.e. it has the catalytic triad: Ser, 
His, and Asp), which is responsible for catalytic activity and inhibitor binding (Irigoyen et al., 1999). 
•degradation of ECM
•activation of growth factors
•activation of cell signaling
•regulation of uPA activity pro-uPA
pro-tPA
uPAR
uPA
tPA
plasmin
PAI-1, PAI-2, PAI-3, PN-1
2-antiplasmin
plasminogen
•degradation of ECM
•activation of MMPs
•activation of growth factors
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The N-'(-chain contains five homologous kringle domains that mediate substrate, inhibitor and 
receptor binding. 
Fibrin is the main target of active plasmin but plasmin is a relatively non-specific protease which
can degrade a wide variety of proteins including ECM and basement membrane molecules, such as
fibronectin, laminin (Liotta et al., 1981a), vitronectin (Chain et al., 1991), proteoglycans (Mochan and 
Keler 1984), fibrin (Dudek et al., 1970), collagen (Liotta et al., 1981b; Goldfarb et al., 1986) and
neural cell adhesion molecule (NCAM; Endo et al., 1999). Plasmin can also activate other proteases, 
including matrix metalloproteases MMP-1, MMP-3, MMP-9, MMP-10, and MMP-13 (reviewed by 
Linjen et al., 2001). Plasmin also possesses the capacity to activate latent growth factors such as TGF-
 	Lyons et al., 1990; Taipale et al., 1992) and fibroblast growth factor (FGF; Saksela and Rifkin, 
1990). The activity of plasmin is regulated primarily by (2-antiplasmin, but plasmin activity can be 
also modulated by plasminogen receptors. Several cell-type specific plasminogen receptors have been 
identified such as (-endolase (in neuronal membranes; Miles et al., 1991; Nakajima et al., 1994), 
annexin II (Hajjar, 1994), actin (Dudani and Ganz, 1996), tissue factor (Fan et al., 1998), and integrins 
() (Pluskota et al., 2004) ( (Lishko et al., 2004). The interaction of plasminogen with most 
of its cellular receptors accelerates its conversion to plasmin and protects the protein from inactivation 
by inhibitors.
2.4.1.1 Plasminogen expression in the nervous tissue
Plasminogen was first identified from rat microglial-conditioned medium and it was later found that 
microglia-derived plasminogen has a neurotrophic-like effect on neurons (Nakajima et al., 1992ab; 
1993). In fact, plasminogen enhances neurite outgrowth in culture conditions, the survival and 
maturation of dopaminergic mesencephalic neurons and dopamine uptake of mesencephalic neurons in 
culture conditions (Nagata et al., 1992; 1993ab; Gutierrez-Fernandez et al., 2009). Basham and Seeds 
(2001) reported that plasminogen was expressed in the cortex, hippocampus and cerebellum of 
neonatal mice. Intracellularly, plasminogen often accumulates in growth cones of developing 
hippocampal neurons and is present in spines of mature neurons (Lochner et al., 2008). The important 
role of plasminogen during development of nervous tissue is supported by brain abnormalities found in 
the brains of plasminogen deficient patients and animals (Schott et al., 1998; Drew et al., 1998).
Conflicting reports have been published involving plasminogen expression in the adult brain. 
Plasminogen mRNA in the adult mouse brain has been identified in cortical neurons, hippocampal 
pyramidal neurons as well as granule cells of the DG, cerebellar Purkinje cells and granule cells 
(Sappino et al., 1993; Tsirka et al., 1997a; Zhang et al., 2002; Basham and Seeds 2001) and the protein 
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expression pattern seems to correlate with the mRNA expression (Basham and Seeds 2001). In 
contrast, Davies et al. (1998) show no evidence of plasminogen production in the rat and mouse brain 
and according to Matsuoka et al. (1998) plasminogen is present in the rat hippocampus only after 
treatments that lead to neurodegeneration. The study of Sálles and Strikland (2002) indicates that 
plasminogen levels are very low in normal mouse brain but increase significantly after an excitotoxic 
injury. Despite these conflicting results, it is clear that plasminogen has a major role in KA-induced 
neuronal damage since plasminogen deficient mice are resistant to KA-induced neurotoxicity (Tsirka 
et al., 1995, 1997) and inhibition of plasmin prevents KA-induced excitotoxicity in the rat striatum 
(Campbell et al., 2004).
2.4.1.2 Effects of plasminogen deficiency or overexpression
The plasminogen knockouts (plg-/-) are born with a normal appearance and survive into adulthood but 
develop spontaneous fibrin lesions in several tissues due to impaired thrombolysis (Bugge et al., 
1995a). These mice also suffer high mortality, wasting, spontaneous gastrointestinal lesions,
conjunctival and corneal lesions, impaired wound healing, diminished monocyte recruitment and 
reduced female fertility (Bugge et al., 1995; Romer et al., 1996; Ploplis et al., 1995, 1998; Drew et al., 
1998). Hydrocephalus has also been observed in plasminogen deficient mice (Drew et al., 1998). These 
pathologies can be eliminated in double knockout mice which have a simultaneous deficiency of 
plasminogen and fibrinogen, indicating that the loss of plasmin-mediated proteolysis can be 
compensated by other proteases with the exception of the events requiring fibrin degradation (Bugge et 
al., 1996a). Hoover-Plow and Rice (1999) and Hoover-Plow et al. (2001) reported that deficiency of 
plasminogen could affect mouse behavior. Thus, plasminogen deficient mice (plg-/-) have increased 
audiogenic seizure susceptibility, increased number of grooming bouts (response to stress) and a
reduced acoustic startle reflex response.
Human plasminogen deficiency has been classified as hypoplasminogenemia/true-type I 
plasminogen deficiency and dysplasminogenemia/type II plasminogen deficiency (Schuster et al., 
2007; Mehta and Shapiro, 2008). In hypoplasminogenemia, the level of plasminogen and its activity is 
decreased (quantitative deficiency). In dysplasminogenemia, the level of immunoreactive plasminogen 
is normal, but the functional activity is reduced (qualitative deficiency; Robbins, 1992). 
Dysplasminogenemia does not seem to lead to a specific clinical manifestation. However, severe 
hypoplasminogenemia is associated with compromised extracellular fibrin clearance during wound
healing, leading to pseudomembraneous (ligneous) lesions on affected mucous membranes (eye, 
middle ear, mouth, pharynx, duodenum, upper and lower respiratory tract and female genital tract). 
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Ligneous conjunctivitis is the most common clinical manifestation of this genetic abnormality
(Schuster et al., 2007). Over 12% of patients with severe hypoplasminogenemia exhibit congenital 
occlusive hydrocephalus, hypoplasia of the cerebellum, and a hypoplastic corpus callosum (Schott et 
al., 1998; Schuster et al., 2007; Mehta and Shapiro, 2008). 
2.4.2 Urokinase type plasminogen activator (uPA)
The name urokinase derives from urine where uPA was first identified, but it is also present in plasma 
and in many tissues (Larsson et al., 1984; Kristensen et al., 1991). In addition to its role in fibrinolysis, 
uPA has been implicated in various events including ovulation (Leonardsson et al., 1995), 
inflammation (Gyetko et al., 1996, 2002; Beck et al., 1999), cell migration and invasion (Andreasen et
al, 1997), wound repair and angiogenesis (Romer et al., 1991; Andreasen et al, 1997).
The human uPA gene is located in chromosome 10 and it is 6.4 kb large (Riccio et al., 1985). The 
human, porcine and mouse uPA genes show an unusually high degree of interspecies sequence 
conservation (Degen et al., 1987). The uPA gene is expressed at low levels in a variety of cells and its
expression can be induced by different signals, such as growth factors, peptide hormones, steroid 
hormones, UV light and cell morphology changes (Nagamine et al., 2005). uPA is produced as a 
single-chain 53 kDa protein, called pro-uPA which is converted into the active, two-chain, form (also 
called high molecular weight uPA) after secretion. The pro-uPA possesses also some enzymatic 
activity but its ability to cleave plasminogen is 200-fold lower than that of the active form (Lijnen et 
al., 1990). Pro-uPA is converted into active uPA form via cleavage of the peptide bond between Lys-
158 and Ile-159. Plasmin is the main activator of uPA but activation can also be achieved, at least in 
vitro, by many other proteins including plasma kallikrein, blood coagulation factor XIIa, T-cell 
associated proteinase, cathepsin B, cathepsin L, nerve growth factor-*, human mast cell tryptase, 
prostate specific antigen, matrix metalloproteinases, vascular endothelial growth factor (VEGF), 
matriptase, hepsin, and some MMPs (Andreasen et al., 1997; Prager et al., 2004; Kilpatrick et al 2006; 
Moran et al. 2006). When pro-uPA is bound to a specific cell surface receptor, urokinase-type 
plasminogen activator receptor (uPAR), it is activated by plasmin much faster than when it is free in 
the fluid phase (Ellis et al., 1989). Thus, in the simplest situation secreted pro-uPA binds to uPAR and 
is subsequently activated by plasmin into uPA, which then converts plasminogen to active plasmin.
The two peptide chains that form the active uPA are linked by disulfide bridges and the molecule 
contains three functional domains: the N-terminal domain homologous to epidermal growth factor, the 
kringle domain, and the C-terminal catalytic domain (Irigoyen et al., 1999). The growth factor-like 
domain is responsible for the uPAR receptor interaction (Stepanova and Tkachuk, 2002). The catalytic
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domain represents the active site of the protease and the kringle domain contains a sequence that 
interacts with the specific inhibitor PAI-1 (Mimuro et al., 1992). In addition to converting pro-uPA to 
active uPA, plasmin can further cleave uPA to a 33 kDa fragment, which lacks the epidermal growth 
factor-like domain and the kringle domains but still retains full activity (low molecular weight uPA;
Irigoyen et al., 1999). Apart from plasminogen, uPA directly activates pro-hepatocyte growth 
factor/scatter factor (HGF/SF) (Naldini et al., 1992; Mars et al., 1993), which is a significant growth 
promoting and survival factor for sensory and motor neurons. Further, uPA can cleave the cell 
associated form of VEGF producing a fragment able to trigger cell proliferation (Plouët et al., 1997).
uPA can also cleave fibrin (Bugge et al., 1996b) and fibronectin (Gold et al., 1992) as well as inhibitor 
PAI- 1 (Nielsen et al., 1986) in a plasminogen-independent manner. uPA has been shown to activate 
other proteases such as MMP-2 (Keski-Oja et al., 1992) and MMP-9 (Zhao et al., 2008). The activity
of uPA is inhibited by plasminogen activator inhibitors (PAIs) and by endocytosis of the receptor 
bound uPA.
uPA is known to be stress responsive and robustly induced during inflammation (Gabay and 
Kushner, 1999). Cancer cell invasiveness is associated with high uPA expression that usually predicts 
aggressive disease (Myöhänen and Vaheri, 2004). Growth factors are well known regulators of 
plasminogen activator production; however, modulation of plasminogen activators by specific growth 
factors varies widely depending on the cell type (reviewed by Trangue et al., 1994; Myöhänen and 
Vaheri, 2004). Previously it was thought that plasminogen activators are secreted rapidly after their 
synthesis. However, Larsson et al. (1984) have reported that uPA is stored in specific cytosolic 
granules in mouse tissues expressing uPA. In human neutrophils uPA is also present in specific 
granules that are exocytosed upon activation (Heiple and Ossowski, 1986).
2.4.2.1 Expression of uPA in the nervous tissue
In mouse brain, there is high uPA expression after birth but the expression declines during the 
development of the brain (Del Bigio et al., 1999). Similarly, a strong expression of uPA in early 
development of a rat is found in the spinal cord and sensory ganglia at a stage linking uPA to axonal or 
dendritic growth (Sumi et al. 1992). This connection has been further supported by cell culture studies 
showing that astrocytes transfected with uPA expressing plasmid which support increased axon growth 
(Muir et al., 1998). Further, the expression of uPA is strongly linked to astrocyte proliferation and 
maturation. The peak of uPA expression coincides with the period of most intense astrocyte 
proliferation both in culture conditions and in the developing rat and mouse brain (Kalderon et al., 
1990). Further, uPA is the primary plasminogen activator in immature rat and mouse astrocytes and its 
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expression decreases with astrocyte maturation (Kalderon et al., 1990). uPA is also expressed in 
human fetal astrocytes in vitro (Le et al., 2003). Phorbol ester, which stimulates proliferation in 
developing rat astrocyte cultures, dramatically increases uPA expression (Tranque et al., 1992a). In 
addition, uPA directly stimulates the proliferation of rat astrocytes in cerebellar microexplants 
(Moonen et al., 1985). Expression of uPA by astrocytomas, which are the most common types of brain 
tumors, is also firmly established and appears to correlate with invasiveness (Gross et al., 1988, Sitrin 
et al., 1990). Neuronal uPA expression has been demonstrated in neurons of the mouse dorsal root 
ganglion, where tPA and uPA are expressed in different subpopulation of neurons and their expression 
and activities are modulated during differentiation (Hayden and Seeds, 1996). 
According to in situ hybridization studies, in normal adult mouse brain, uPA is not very abundant 
and it is mainly localized in neurons in just a few specific sites, primarily the subicular complex, the 
entorhinal cortex and the parietal cortex (layers IV and VI). Minor uPA expression has also been found 
from the basolateral nucleus of amygdala, the anterodorsal thalamic nucleus, the hilus of the dentate 
gyrus, and in the CA3 pyramidal cells of the hippocampus (Masos and Miskin, 1996). In the adult rat 
brain, uPA mRNA distribution differs markedly from the pattern found in mice. According to Masos 
and Miskin (1996), in the normal adult rat brain uPA is also expressed in neurons but it is much more 
abundant than in the mouse brain. It is expressed throughout the neocortex, including the parietal and 
occipital regions, the granular layer of the dentate gyrus and in the pyramidal cells of the hippocampus. 
In addition, most areas of gray matter express low levels of uPA mRNA (Masos and Miskin, 1996). 
These findings are in agreement with previous findings of Dent et al. (1993). Studies showing uPA 
protein expression in the adult brain are scarce. However, the recent study of Iyer et al. (2010) revealed
that in adult human hippocampus, uPA is expressed at low levels in pyramidal neurons and granule 
cells.
2.4.2.2 Effects of uPA deficiency or overexpression
Mice deficient of uPA (uPA-/-) develop normally, are fertile and have a normal life span (Carmeliet et 
al., 1994). However, they occasionally develop spontaneous fibrin deposits in normal and inflamed 
tissue and display deficient plasmin-mediated macrophage function (Carmeliet et al., 1994). 
Accordingly, uPA-/- mice are more susceptible to several infectious agents due to failure of 
inflammatory cell recruitment (Gyetko et al., 1996, 2002; Beck et al., 1999). Interestingly, studies with 
uPA-/- mice have indicated that uPA expression/activity can be beneficial for recovery of several 
tissues after trauma. Lluis et al. (2001) and Sisson et al. (2009) noted that that uPA-/- mice display
severe deficits in muscle regeneration after damage, characterized by decrease in myoblast 
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proliferation and muscle fiber generation. Further, uPA-/- mice show delayed recovery of hindlimb
function (more severe than tPA-/- and plg-/- mice) in a mouse model of sciatic nerve crush (Siconolfi 
and Seeds, 2001a) and more extensive cortical brain damage in 2 weeks after traumatic brain injury 
(Morales et al., 2006). In contrast, uPA deficiency does not seem to have effect on lesion size acutely
(3 d) after experimental cerebral infarction (Nagai et al., 2008) or the severity of neuronal damage 
acutely after intrahippocampal KA administration (Tsirka et al., 1997b), however long term effects 
have not been studied.
Studies indicate that uPA deficiency causes alterations in the regeneration of blood vessels. In uPA-
/-mice, VEGF fails to stimulate angiogenesis in infarcted hearts (Heymans et al., 1999). Further, 
arteriogenesis was strongly reduced in uPA-/- mice in a mouse model of hindlimb ischemia (Deindl et 
al. 2003), while uPA gene transfer augmented angiogenesis in a rat model of myocardial infarction 
(Traktuev et al., 2007). uPA may also affect blood vessels/angiogenesis by protecting endothelial cells 
from apoptosis as recently shown by Prager et al. (2009).
Transgenic mice 	()+, producing high levels of uPA in neurons in sites implicated in learning 
and memory are impaired in tasks of spatial, olfactory and taste-aversion learning while displaying 
normal sensory and motor capabilities (Meiri et al., 1994). In addition, these mice exhibit reduced food 
consumption, body weight and size, increased longevity, enhanced capacity to trigger apoptosis in 
liver, reduced incidence of spontaneous or carcinogen-induced tumors or preneoplastic lesions in 
several tissues (Miskin and Masos, 1997; Tirosh et al., 2004).
2.4.3 Tissue-type plasminogen activator (tPA)
The mRNA for tPA is 2.7 kb and encodes a glycoprotein with a molecular mass of 70 kDa. tPA is 
secreted in a single chain form that is converted into an active two-chain form by a single proteolytic 
cleavage by plasmin (Arg-275 – Ile-276). However, unlike uPA, the single chain tPA possesses 
significant activity (Nienaber et al., 1992). tPA is also a more complex molecule than uPA, containing 
five functionally distinct domains: the amino-terminal domain (or fibronectin-like domain), an EGF-
like domain, two kringle regions (K1 and K2), and a serine protease region (Irigoyen et al., 1999). The 
growth factor domain, catalytic domain and the kringle domains are similar to those found in uPA. K2 
and the fibronectin-like domain are responsible for tPA’s high affinity for fibrin and its activation by 
fibrin (Irigoyen et al., 1999). When tPA is bound to fibrin, its catalytic activity is greatly enhanced 
which leads to efficient plasminogen activation. This specific ability of tPA to locally activate 
plasminogen on the surface of fibrin has led to its successful use as a thrombolytic agent in myocardial 
infarction and ischemic stroke (Collen, 2001).
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The vascular endothelium is the main source of endogenous tPA in adults but tPA is not only 
present in blood but also in most tissues including brain (Rickles and Strickland, 1988; Teesalu et al., 
2002). The main role of tPA is in fibrinolysis and the expression of tPA is induced in situations caused 
by or prone to thrombosis, such as ischemia, wounding and ovulation (Irigoyen et al., 1999). However, 
several studies have highlighted the important role of tPA in reorganization events within the CNS 
such as neurodegeneration (Tsirka et al., 1995, 1996), neuronal migration (Seeds et al., 1999) and MFS 
(Wu et al., 2000).
2.4.3.1 Expression of tPA in the nervous tissue
During development of a mouse, tPA is expressed by cells in the floor plate in the developing nervous 
system (Sumi et al. 1992). There are several studies demonstrating that the most profound expression 
of tPA is found during neuronal migration and axonal growth (Krystosek and Seeds, 1981; Moonen et 
al., 1985; Friedman and Seeds, 1994; 1995; Ware et al., 1995a). In cell culture, neurons that produce 
more tPA move much faster and produce more neurites than normal neurons (Pittman and
DiBenedetto, 1995). In adult brain, tPA is clearly the major plasminogen activator type in normal rat 
and mouse brain when enzymatic activity is measured (Masos and Miskin, 1996; Meiri et al., 1994). 
tPA mRNA is expressed in normal mouse brain in neurons in the olfactory bulb, cerebellum (Purkinje 
cells), thalamus, hypothalamus, hippocampus and neocortex (Sappino et al., 1993, Friedman and 
Seeds, 1995; Ware et al., 1995b). tPA protein is found in vascular tissue throughout the mouse brain 
and in the meninges, neuropil of the central nucleus, the bed nucleus, hippocampus and the 
hypothalamus (Salles and Strikland, 2002). Within the mouse hippocampus, tPA protein is clearly 
present in the mossy fiber pathway and blood vessels (Sappino et al., 1993; Salles and Strikland, 
2002). Surprisingly, the expression pattern of tPA in the rat brain differs markedly from that in the 
mouse brain. In the rat brain, tPA mRNA is expressed in cerebral ventricular ependyma, meninges, 
blood vessels and Purkinje cells of the cerebellum (Ware et al., 1995b) but the rat mossy fiber pathway 
does not express significant levels of tPA under basal conditions (Salles and Strikland, 2002). In the 
normal human CNS, tPA is expressed in neurons in thalamus, cortex of cerebellum, pontine nuclei, 
neocortex, limbic system, and medulla oblongata (Teesalu et al., 2004; Iyer et al., 2010). In the human 
hippocampus, tPA is expressed in pyramidal cells and granule cells and similar to the situation in the
rat brain, the human hippocampus lacks the tPA expression in the mossy fiber pathway (Salles and 
Strikland, 2002; Iyer et al., 2010). The expression of tPA is induced by seizures, kindling and long 
term potentiation (LTP) in the rat and mouse brain (Qian et al., 1993; Carroll et al., 1994; Salles and 
Strikland, 2002).
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2.4.3.2 Effects of tPA deficiency or overexpression
The tPA knock-out mice (tPA-/-) are capable of going through embryonic development and the
phenotype of the adult animal is normal (Carmeliet et al., 1994). In early studies, only reduced 
pulmonary plasma clot lysis was observed in these mice (Carmeliet et al., 1994). However, 
subsequently it was found that tPA knockouts are resistant to kainate- induced neurotoxicity (Tsirka et 
al., 1995), show attenuated microglial activation (Tsirka et al., 1995), retarded cerebellar granule cell 
migration (Seeds et al., 1999) and decreased MFS (Wu et al., 2000). According to Huang et al. (1996) 
tPA-/- mice exhibit a selective reduction in the late phase of LTP in hippocampal slices in both the 
Schaffer collateral-CA1 and mossy fiber-CA3 pathways. Further, according to Frey et al. (1996), tPA-
/- mice exhibit a different form of LTP, which is mediated by NMDA receptor dependent modification 
of gamma-aminobutyric acid (GABA) transmission in the CA1 region. In accordance with these 
findings, tPA deficient mice suffer learning impairments (Huang et al., 1996; Pawlak et al., 2002; 
Seeds et al., 2003; Calabresi et al., 2000). Overexpression of tPA has been shown to enhance LTP and 
improve performance in the Morris water maze (Madani et al., 1999). 
2.4.4 Urokinase-type plasminogen activator receptor (uPAR)
uPAR is expressed in a variety of cell types in vivo, including monocytes and macrophages, 
granulocytes, keratinocytes, trophoblasts, myofibroblasts and several types of cancer cells (Solberg et 
al., 2001). Under normal physiological conditions, basal expression levels of uPAR are relatively low 
in various mouse tissues that have been investigated but stimulated in tissues under active remodeling
(Solberg et al., 2001).
The mRNA coding for uPAR is 1.4kb and uPAR is synthesized as a single polypeptide chain of 
313 amino acid residues, with a 21-residue signal peptide. Interestingly, uPA regulates the expression 
of uPAR at the transcriptional and post-transcriptional levels (Ragno, 2006). The fully processed form 
of uPAR consists of 283 amino acids, is heavily glycosylated and has a molecular weight of 
approximately 55 kDa (Ploug et al., 1991). uPAR is attached to the cell surface extracellularly through 
a glycosylphosphatidylinositol (GPI) anchor (Ploug et al. 1991). The uPAR protein can be structurally 
divided into three domains (D1, D2 and D3). The amino-terminal D1 domain directly contacts uPA, 
but the linker D2 domain and the carboxy-terminal D3 domain are also needed for high affinity 
binding of uPA (Blasi and Carmeliet, 2002). In addition to the membrane-anchored form, uPAR can be 
released from the plasma membrane by cleavage of the GPI anchor and can be found as a soluble 
molecule (Blasi and Carmeliet, 2002). uPAR can also be cleaved to yield a separate D1 fragment and a 
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D2D3 fragment (Blasi and Carmeliet, 2002; Høyer-Hansen et al., 1992). In vitro, this cleavage can be 
achieved with several proteases like trypsin, chymotrypsin, cathepsin G, elastase, metalloproteases, 
uPA and plasmin (Sidenius et al., 2000; Ragno 2006).  The D2D3 fragment possesses direct 
chemotactic activity (Blasi and Carmeliet, 2002; Solberg et al., 2001)
uPAR bound to uPA can also bind the serum and ECM protein vitronectin, which is a ligand of 
(v3 integrin (Waltz et al, 1994). Co-immunoprecipitation studies have revealed that uPAR can form
complexes with several integrin families, such as 1,  2,  3 and 5 (Ragno 2006). Integrins are 
receptors that mediate attachment between the cell and ECM and also between cells. They also play a 
role in cell signaling and thereby define cellular shape, mobility, and regulate the cell cycle. Integrins 
have been also implicated in regulation of synaptic plasticity (Dityatev and Schachner, 2006). Other 
transmembrane molecules found to interact with uPAR include caveolin and some G-protein-coupled 
receptors (Blasi and Carmeliet, 2002); Thus, binding to these molecules enables uPAR to affect several 
cellular functions (reviewed in Blasi and Carmeliet, 2002; Ragno 2006).
2.4.4.1 uPAR expression in the nervous tissue
In the developing mouse (P8-P12) cortex, hippocampus and striatum uPAR is expressed in the
majority of large and medium size neurons (Del Bigio et al., 1999). In differentiating mouse dorsal 
root ganglion cultures, uPAR is highly expressed in neurons and to a lesser extent in Schwann cells 
and fibroblasts (Hayden and Seeds, 1996). In addition, also astrocytes obtained from P1 mice and 
cultured for 5 days in vitro express uPAR (Del Bigio et al., 1999). Similarly to mouse, fetal human 
astrocytes express uPAR in vitro (Le et al., 2003). However, in adult mouse and human brain, the 
expression of uPAR is low or undetectable (Del Bigio et al., 1999; Beschorner et al., 2000; Gveric et 
al., 2001; Liu et al., 2010; Iyer et al., 2010). In normal human brain, uPAR expression has been
indentified in the epithelial cells of choroids plexus, endothelial cells, and arachnoid cells (Beschorner 
et al., 2000). Expression of uPAR has also been demonstrated in cultured human microglia obtained 
from adults operated due to contractible epilepsy, however no uPAR mRNA or protein expression was 
detected when microglia was studied immediately ex vivo (Washington et al., 1996). Taken together, 
these studies suggest that uPAR expression occurs during pre- and postnatal development both in 
rodent and human brain but expression in matured neurons and glia is low.
2.4.4.2 Effects of uPAR deficiency or overexpression 
uPAR knockout mice develop normally, survive to adulthood and breed normally (Bugge et al., 1995b)
but display defective recruitment and migration of neutrophils and lymphocytes (Gyetko et al., 2000, 
28
2004). These mice show also increased susceptibility to seizures, heightened anxiety, and diminished 
social interaction (Levitt et al., 2005). Detailed immunohistochemical studies revealed 50% reduction 
in GABAergic interneurons in frontal and parietal cortices of uPAR-/- mice and interestingly more
than 90% of the lost cells represent the parvalbumin subtype of interneurons (Powell et al., 2003). 
There is data indicating that uPAR deficiency can affect the development/maturation of interneurons 
rather than neuronal migration (Powell et al., 2003; Eagleson et al., 2005). A deficiency of uPAR can 
protect from damage evoked by ischemia as the size of brain lesion is smaller (at 3 days) in uPAR-/-
mice than in wt mice after permanent MCAO (Nagai et al., 2008).
2.4.5 Plasminogen activator inhibitors
Unrestrained secretion of plasminogen activators and the resulting uncontrolled proteolytic activity 
would be hazardous to cells, and as one form of protection, cells often secrete a surplus of inhibitors. 
The inhibitors of plasminogen activators, the plasminogen activator inhibitors (PAIs), are members of 
the serine protease inhibitor superfamily (SERPIN). The inhibitors include PAI-1, PAI-2, and to a 
lesser extent protease nexin-1 (PN-1) and protein C inactivator (PCI, also called PAI-3). They all have 
a peptide bond for target proteases which resembles a pseudo-substrate, coupling them irreversibly in 
the inactive conformation with their target protein (Irigoyen et al, 1999). 
2.4.5.1 PAI-1
Plasminogen activator inhibitor 1 (PAI-1) is considered to be the primary physiological inhibitor of 
uPA and tPA and it reacts quickly with both proteins (Andreasen et al., 1990). PAI-1 reacts both with 
single- and two-chain forms of tPA and uPA (Andreasen et al., 1990; Manchanda and Schwartz, 1995). 
In addition to inhibition, PAI-1 binding to uPAR-bound uPA induces the complex internalization and 
thus modulates uPA-uPAR levels on cell surface (Irigoyen et al., 1999). PAI-1 is secreted as a 54 kDa 
protein. After secretion, PAI-1 is quickly transformed into a conformation that is unable to bind with 
plasminogen activators, but the active form can be stabilized by vitronectin or heparin binding
(Irigoyen et al., 1999). Unlike the plain secreted form, the substratum-bound immobilized inhibitor 
remains active in the ECM for a prolonged time (Irigoyen et al., 1999). 
PAI-1 is rich in plasma and PAI-1 mRNA is highly expressed in the aorta, adipose tissue, heart, 
and lungs of mice (Sawdey and Loskutoff, 1991). Elevated levels of plasminogen activator inhibitor-1
(PAI-1) are associated with a poor prognosis in different types of cancers (Andreasen et al., 2000). 
This may be due to the ability of PAI-1 to stimulate cell migration (Stahl et al., 1997), modulate cell 
adhesion (Palmieri et al., 2002) and to stimulate angiogenesis (Bajou et al., 1998; Gutierrez et al., 
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2000), which all promote tumor growth and spread. There is low expression in normal adult mouse and 
human brain but it can be induced by various substances and brain pathology (Sawdey and Loskutoff, 
1991; Masos and Miskin 1997; Hino et al., 2001). Studies indicate that PAI-1 is neuroprotective 
through plasminogen activator inhibition but also has an anti-apoptotic function that is independent 
from plasminogen activation (Soeda et al., 2008). Despite the suggested multiple functions, PAI-1
knockout (PAI1-/-) mice are viable, produce similar sizes of litters as control mice, and show no 
apparent macroscopic or microscopic histological abnormalities (Carmeliet et al., 1993). In human 
CSF, increased PAI-1 levels are connected to Alzheimer's disease, cerebral infarction, CNS infection, 
alcohol withdrawal seizures and CNS neoplasia (Sutton et al., 1994).
2.4.5.2 PAI-2
Plasminogen activator inhibitor type 2 (PAI-2) reacts with both uPA and tPA but more efficiently with 
uPA but more slowly than PAI-1 (Andreasen et al., 1990). PAI-2 has an unusual feature of existing in 
both secreted and cytosolic forms. Thus, newly synthesized 47 kDa PAI-2 remains intracellular, with 
only a fraction of PAI-2 secreted as a glycosylated product (60-70 kDa) outside the cell (Kruithof et 
al., 1995). The distribution of intracellular and secreted forms of PAI-2 depends on the cell type, 
culture conditions, and differentiation state of the cell (Mikus and Ny, 1996). 
In vivo functions of PAI-2 are less well known than those of PAI-1. PAI-2 is thought to serve as a 
primary regulator of plasminogen activation in the extravascular compartment since it is not usually 
found in plasma. The high levels of PAI-2 expression in macrophages and keratinocytes point to a role 
in the regulation of the inflammatory response, keratinocyte differentiation, and/or wound healing
(Mikus and Ny, 1996). Its expression in the human trophoblast, suggests a role in placental 
maintenance or embryo development (Mikus and Ny, 1996). The cytosolic form of PAI-2 has been 
claimed to be a protective agent against apoptosis mediated by tumor necrosis factor (	-'.!'%
al., 1995). However, homozygous PAI-2-deficient mice exhibit normal development, survival, and 
fertility and are also indistinguishable from normal controls in their response to a bacterial infectious 
challenge or endotoxin infusion (Dougherty et al., 1999). Similarly to PAI-1, increased expression of
PAI-2 seems to play a role in tumor growth and metastasis (Kruithof et al., 1995; Dougherty et al., 
1999).
In the normal adult mouse brain, PAI-2 mRNA has been found to be localized to a single site 
within the shell of nucleus accumbens (Sharon et al., 2001). However, KA induces intense expression 
of PAI-2 in several brain areas including the pyramidal cell layer of the hippocampus (Sharon et al., 
2002). In the human brain, expression of PAI-2 has been found in microglia (Akiyama et al., 1993).
30
2.4.6 Neuropathology of the plasminogen system
2.4.6.1 Plasminogen system and excitotoxic injury
There are several studies indicating that the expression and activity of plasminogen system 
components are modulated after KA-induced excitotoxic injury, however their role is still unclear.
Qian et al. (1993) was one of the first to reveal that KA-induced seizures strongly induce the 
expression of tPA in the whole brain of mice.  Later, Masos and Miskin (1997), Matsuoka et al., 1998, 
Nagai et al. (1999a), Endo et al. (1999), Sharon et al. (2001, 2002) and Sallés and Strikland (2002) 
demonstrated that plasminogen, uPA, tPA, PAI-1 and PAI-2 expressions are upregulated in the rat 
or/and mouse brain following KA-mediated excitation. More recently, Cunningham et al. (2009) 
reported increased uPAR mRNA and protein expression but unchanged expression of uPA, tPA and 
PAI-1 in the mouse hippocampus after i.h. KA-injection. The neurotoxicant, trimethyltin (TMT), has 
been shown to increase uPA mRNA expression in the rat hippocampus and frontal lobe, this being
followed by increased uPA enzymatic activity (Dencoff et al., 1997). 
Knockout mice have been employed to elucidate the role of different components of the
plasminogen system after brain damaging insults. In these studies, plasminogen and tPA knockout 
mice have been found to be resistant to KA-induced neurotoxicity (Tsirka et al., 1995, 1997a). Further, 
inhibition of plasmin can prevent excitotoxicity in the rat striatum (Campbell et al., 2004). The role of 
tPA in neurodegeneration has been widely studied and it seems that tPA can act as a neurodegenerative 
agent by using several pathways. According to one theory, tPA activated plasmin participates in 
excitotoxic neuronal death by degrading the ECM protein laminin and disrupting the cell-matrix 
contact (Chen and Strickland, 1997; Nagai et al., 1999a). tPA has also plasmin independent excitotoxic
effects. tPA has been shown to cleave the NR1 subunit of the NMDA receptor and may contribute to 
neuronal degeneration via an enhanced NMDA-evoked Ca2+-influx (Nicole et al., 2001; Fernandez-
Monreal et al., 2004). Further, the neurodegenerative effects of tPA have also been linked to microglial 
activation. Tsirka et al. (1995) and Rogove et al. (1999) reported that tPA-/- mice exhibited attenuated 
microglial activation. There is data to suggest that tPA plays different roles after KA injection 
depending on whether it is released by neurons or microglia (Siao et al., 2003). According to this
hypothesis, tPA secreted from injured neurons would act as a cytokine to activate microglia. Activated 
microglia then secrete additional tPA, which promotes extracellular matrix degradation, 
neurodegeneration, and  further proliferation of microglia (Siao et al., 2003).
Although uPA has been found to be upregulated after excitotoxic injury, it has not been as widely 
studied as tPA. This may be due to the report of Tsirka et al. (1997), showing that uPA deficiency does 
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not protect from the neuronal damage occurring acutely after i.h. KA. In addition, PAI-1 deficiency 
does not affect the acute KA-induced damage (Salles and Strikland, 2002).
2.4.6.2 Plasminogen system and traumatic injury
Several studies have described the induction of plasminogen system expression or activity in the 
nervous tissue after traumatic injury. Hemorrhagic injury evokes an uPA activity increase 16 hours to 7 
days in the rat brain (Rosenberg et al., 1994). Armstead et al. (2009) reported that uPA is upregulated 
in neurons and glia in newborn and juvenile pig brain after fluid-percussion injury (FPI). Further, uPA 
activity was induced in the rat facial nucleus after axotomy of the facial nerve and neurons contribute
most of the expression (Nakajima et al., 1996, 2005). The data of Morales et al. (2006) indicate that the 
induction of uPA expression/activity after trauma is beneficial for recovery since uPA-/- mice have
larger cortical damage than Wt mice 2 weeks after TBI. In agreement, uPA is crucial in the synaptic 
plasticity associated with the crossed phrenic phenomenon (CPP) and recovery of respiratory function 
following spinal cord injury (Seeds et al., 2009). In contrast, the function of tPA after trauma appears 
to be neurodegenerative. Thus, tPA-/- mice are protected in terms of smaller cortical lesions and 
reduced edema after TBI (Mori et al., 2001). A tPA deficiency also reduces neural damage in a mouse 
model of spinal cord injury (Abe et al., 2003). There are few studies of uPAR expression and function 
after trauma. However, studies of human autopsy tissue show a transient upregulation (peaking 3-4
days after trauma) of uPAR protein in astrocytes, endothelial cells of blood vessels, invading 
granulocytes, and activated microglia/macrophages following TBI and focal cerebral infarction 
(Beschorner et al., 2000).
In the peripheral nervous system, the plasminogen system (uPA, uPAR, tPA) is induced and it 
seems to be important in the recovery after trauma (Siconolfi and Seeds, 2001ab). In plg-/- and tPA-/-
mice axonal demyelination is enhanced after sciatic nerve crush and this occurs in parallel with the 
increase in fibrin deposition (Akassoglou et al., 2000). Mice lacking plasminogen or its activators
(uPA or tPA) display also a delayed functional recovery after sciatic nerve crush (Siconolfi and Seeds, 
2001a).
2.4.6.3 Plasminogen system and ischemia
The plasminogen system has been rather extensively studied in stroke since tPA is used as a 
thrombolytic agent to treat stroke patients. According to most studies, uPA is the main plasminogen 
activator induced in response to cerebral ischemia in mice, rats and non-human primates (Ahn et al., 
1999; Rosenberg et al., 1996; Cinelli et al., 2001; Hosomi et al., 2001). According to Rosenberg et al. 
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TABLE 2. Experimental studies profiling the expression of the plasminogen system components after brain 
damaging insults
Model/animal Brain area studied Finding Reference
Hemorrhagic injury in 
the rat brain
whole brain uPA activity increased 16 h to 7 d. Rosenberg et al. 
(1994)
TMT injection in the rat 
brain
hippocampus 
and FL
uPA activity increased in the hippocampus at 
12 and 96 h, and in FL at 96 h after injury.
Dencoff et al. 
(1997)
KA induced SE in 
mouse
(i.p.)
whole brain uPA and PAI-1 mRNA and enzymatic 
activity elevated in limbic structures and 
cortex.
Masos and Miskin 
(1997)
KA induced SE in 
mouse (lateral ventricle)
hippocampus tPA activity increased in CA3 area 7 h after 
KA.
Endo et al. (1999)
KA induced SE in 
mouse
(i.p.)
whole brain KA induced plasminogen mRNA expression 
(2-24 h) in neuronal cells in layers II–III of 
the neocortex, olfactory bulb, anterior 
olfactory nucleus, piriform cortex, 
caudate/putamen and accumbens nucleus 
shell, throughout the amygdaloid complex, 
and in the CAI/CA3 subfields of the 
hippocampus. Expression of PAI-2 was 
induced similarly to plasminogen.
Sharon et al. (2001, 
2002)
KA induced SE in 
mouse (i.h.)
whole brain tPA mRNA and protein expression induced 
in the ipsilateral CA1 neurons. Peak of 
expression was observed 5-8 h after KA and 
expression returned to baseline at 24-48 h. 
PAI-1 protein expression increased 24 h after 
KA in the hippocampus.
Sallés and Strikland 
(2002)
electrical stimulation 
(hippocampus) induced 
SE in rat
DG and EC tPA and uPA gene-expression upregulated in 
the DG and EC 1 d and 1 wk after SE.
Gorter et al. (2007)
KA induced SE in 
mouse (intracerebral)
hippocampus Increased expression of uPAR mRNA and 
protein 48 h after KA.
Cunningham et al. 
(2009)
MCAO in rat whole brain Increased uPA activity at 12 h, 24 h and 5 d
after MCAO. tPA activity decreased 1 h, 12h
and 24 h after MCAO.
Rosenberg et al. 
(1996)
MCAO in mouse whole brain PAI-1 mRNA expression increased 2-25 h 
after ischemia. No change in uPA and tPA 
mRNA expression. uPA activity increased 4-
24 h after MCAO.
Ahn et al. (1999)
MCAO in mouse cerebral 
cortex
Increased PAI-1 mRNA expression 24h and 
3 d after ischemia. No change in tPA, PN-1
or neuroserpin expression.
Docagne et al. 
(1999)
(continues)
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(Table 2. continues)
Model/animal Brain area studied Finding Reference
MCAO in rat cerebral 
cortex, 
hippocampus
mRNA levels of tPA and uPA increased in 
the cortex, and uPA mRNA upregulated in
the hippocampus after MCAO.
Ito et al. (2000)
MCAO in mouse whole brain uPA and tPA expressing cells accumulated 
around the lesion site. uPA activity increased 
in the lesion area.
Cinelli et al. (2001)
MCAO in non-human 
primate
basal ganglia uPA activity and amount of antigen
increased significantly at 1 h and tPA 
activity decreased transiently at 2 h after 
MCAO. Amount of PAI-1 antigen increased 
at 2 h.
Hosomi et al., 
(2001)
spontaneously 
hypertensive stroke-
prone rats
cerebral 
cortex
Increased uPA mRNA and protein 
expression and activity 3 d after stroke. No 
change in tPA or PAI-1 expression.
Sironi et al. (2003)
MCAO in mouse cerebral 
cortex
Increased uPAR mRNA and protein 
expression 12-72 h after MCAO.
Nagai et al. (2008)
Hypoxia-ischemia in rat hippocampus 
and cortex
tPA, uPA and PAI-1 mRNA expression 
upregulated in hippocampus 4 h after 
ischemia in rat pups. tPA and uPA activity 
upregulated up to 24 h after ischemia in the 
cortex of rat pups but no change in adult rats.
Adhami et al. 
(2008)
TBI in human lesion site 
and 
surrounding 
tissue
Transient upregulation (peaking at 3-4 d) of 
uPAR protein in astrocytes, endothelial cells 
of blood vessels, invading granulocytes, and
activated microglia/macrophages after 
trauma.
Beschorner et al. 
(2000)
TBI in rat frontal cortex Increased mRNA expression of uPAR and 
uPA at 24 h after injury.
Rall et al. (2003)
TBI in rat whole brain Increased uPAR mRNA levels in the 
ipsilateral somatosensory cortex and 
surrounding the lateral ventricle at 24h after 
injury.
Dash et al. (2004)
LPS injection in mouse 
(intracerebral)
hippocampus Increased expression of uPAR and PAI-1
mRNA 24 h after LPS. Increased expression 
of uPAR protein at 8-72 h.
Cunningham et al. 
(2009)
Abbreviations: DG, dentate gyrus; EC, entorhinal cortex; FL, frontal lobe; i.h., intrahippocampal; i.p., 
intraperitoneal; KA, kainic acid; LPS, lipopolysaccharide; MCAO, middle-cerebral artery occlusion; SE, status 
epilepticus; TMT, trimethyltin.
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(1996), the enzymatic activity of uPA is increased up to 5 days in the rat brain after middle-cerebral 
artery occlusion (MCAO). In contrast, tPA activity is declines possibly due to increased PAI-1
expression and complex formation with tPA (Rosenberg et al., 1996; Ahn et al. 1999; Docagne et al., 
1999; Hosomi et al., 2001). Ito et al. (2000) reporte and increased gene-expression of both tPA and 
uPA in the rat cerebral cortex after MCAO but upregulated uPA expression in the hippocampus. 
According to Nagai et al. (2008) uPAR mRNA and protein expression is upregulated in the ipsilateral 
cerebral cortex within 12h, and remains elevated for up to 3 days after MCAO in rats.
Involvement of the plasminogen system in cerebral ischemia has been also widely studied by using 
knockout mice. According these studies, a deficiency of plasminogen and PAI-1 leads to more 
extensive damage after MCAO (Nagai et al., 1999). In accordance, (2antiplasmin deficient mice 
exhibit smaller lesions (Nagai et al., 1999). Further, a deficiency of uPAR can protect from the damage 
caused by ischemia as the size of the brain lesion is smaller in uPAR-/- mice than in Wt mice after 
permanent MCAO (Nagai et al., 2008). In contrast, uPA deficiency does not seem to have any effect 
on lesion size (Nagai et al., 1999). Conflicting results have been obtained with tPA deficient mice.
Wang et al. (1998) and Nagai et al. (1999) reported that tPA-/- mice displayed reduced brain lesion 
after MCAO. The same effect could be obtained by inhibiting tPA and NMDA NR1 subunit interaction 
in mice (Benchenane et al., 2007).  However, in the study of Tabrizi et al. (1999) tPA knockouts 
actually experienced larger infarct areas than Wt littermates. The conflicting results in different studies
may be due to the different mouse strains used as well lack of proper control mice (see Tabrizi et al., 
1999). In these studies the lesion volume is usually measured within few days after MCAO and there is 
nothing known about the long term effects of the components of the plasminogen system.
2.4.6.4 uPA and uPAR in brain affecting diseases
The plasminogen system is involved in several brain pathologies. Increased expression and a clear
connection to malignancy has been established for uPA and uPAR in brain tumors (MacDonald et al.,
1998; Yamamoto et al., 1994ab; Gladson et al., 1995). As in other cancer types, uPA and uPAR 
facilitate brain tumor cell invasion and migration. Since the plasminogen system is linked to 
immunodefence function as well as degradation of proteins, it is not surprising that several studies 
have identified a connection with upregulated expression/activity of uPA and uPAR and multiple 
sclerosis (MS)(Akenami et al., 1997, 1999; Cuzner and Opdenakker, 1999; Teesalu et al., 2001). 
According to Gveric et al. (2001), perivascular mononuclear cells and macrophages are the source of 
increased expression and activity of uPA and uPAR in the brain samples obtained from MS patients. 
Increased expression of uPAR in cerebral microvessels (Dore-Duffy et al., 1993) and microglia 
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(Washington et al., 1996) in MS patients has also been reported. Knockout animal studies confirm that 
the plasminogen system can contribute to the development of MS through both inflammatory and 
degenerative processes. uPAR or PAI-1 deficiency is able to delay the development of the disease 
whereas tPA deficiency causes more rapid progression and more severe disease (East et al., 2005, 
2008). However, uPAR-/- mice develop chronic disease which is a consequence of the steadily 
increasing inflammation, increased levels of uPA and greater demyelination (East et al., 2005).
The plasminogen system is also involved in the pathology of Alzheimer's disease (AD). In human 
brain, upregulated uPAR protein expression has been found in cortical neurons (Deininger et al., 2002) 
as well as microglia (Walker et al., 2002) of patients with AD. Furthermore, plasmin levels are reduced 
in the hippocampus and cortex of AD patients (Ledesma et al., 2003). ,'./'brils 
(amyloid peptide), i.e. the main constituent of plaques commonly found in the brains of AD patients, 
and thus plasmin 0% %0&%$%.'1/'&%%2'.'3'.&&.%''%
(Tucker et al., 2000). Amyloid peptide also induces tPA and uPA expression in vitro and in vivo and 
addition of tPA, uPA and plasminogen to cell cultures has reduced Aß neurotoxicity (Tucker et al., 
2002; Dotti et al., 2004). 
Increased uPAR protein expression has been found in cortical neurons of patients with Creutzfeld-
Jacobs disease (Deininger et al., 2002). In accordance, the expression of uPA and uPAR mRNA as 
well as protein levels increase during the progression of prion disease in mice, followed by an increase 
in uPA activity in the brain (Cunningham et al., 2009). It is not clear whether these changes contribute 
to disease progression or are merely compensatory reactions. Contradicting results have been reported 
on the effect of plasminogen deficiency on prion disease development (Cunningham et al., 2009).
Recently, uPA and uPAR have also been linked to epilepsy and developmental malformations of 
the brain. Powell et al. (2003) and Eagleson et al. (2005) have shown that a uPAR deficiency can cause
deficits in interneuron development and evoke epilepsy in mice. In humans, increased uPAR protein 
expression has been demonstrated in the frontal cortex of patients with intractable frontal lobe epilepsy 
(Liu et al., 2010). Further Iyer et al. (2010) reported increased uPA and uPAR expression in the 
hippocampus of TLE patients with hippocampal sclerosis as well as in samples of focal cortical 
dysplasia and cortical tubers from patients with Tuberous Sclerosis Complex. In addition, mutations in 
the recently identified ligand for uPAR, SRPX2 (Sushi-Repeat Protein, X-linked 2), can cause 
Rolandic epilepsy with speech impairment (RESDX syndrome) or a developmental defect of the 
speech cortex (bilateral perisylvian polymicrogyria) (Royer-Zemmour et al., 2008).
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3. AIMS OF THE STUDY
This study is a part of a large project aiming to elucidate the molecular alterations that occur during 
epileptogenesis. The focus of this study was first to characterize gene expression changes that occur in 
the rat temporal lobe and hippocampus during SE-induced epileptogenesis and epilepsy. One of the 
genes, uPA, was chosen for further studies as it demonstrate one of the most extensive upregulation
patterns and had been implicated in several reorganization events in various tissues. Studies were 
designed to investigate the expression and activity of uPA and its receptor uPAR in the normal rat 
brain and during epileptogenesis and to elucidate the role of uPA in the cellular changes that occur 
during epileptogenesis.
This series of studies was aimed at answering the following questions:
1) How is gene-expression modulated in the rat hippocampus and temporal lobe during SE-induced 
epileptogenesis? (I)
2) What is the expression, cellular distribution and activity of uPA in normal rat brain and during SE-
induced epileptogenesis? (II)
3) What is the expression and cellular distribution of uPAR in normal rat brain and during SE-induced 
epileptogenesis? (III)
4) How does deficiency of uPA affect epileptogenic reorganization events such as neurodegeneration,
neurogenesis and granule cell dispersion in the mouse hippocampus after SE? (IV)
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4. MATERIALS AND METHODS
4.1 Animals
Animal experiments were approved by the Committee for the Welfare of Laboratory Animals of the 
University of Kuopio and by the Provincial Government of Kuopio. All procedures were conducted in 
accordance with the European Community Council directives 86/609/EEC. All efforts were made to 
minimize the number of animals used and to alleviate their suffering.
Rats (I, II, III). Adult male Harlan Sprague-Dawley rats (Harlan, AD Horst, The Netherlands) 
were used (n=108). Rats were housed in a controlled environment (temperature 22±1 °C, humidity 
50%–60%, lights on 07:00–19:00 h) with free access to food and water. 
Mice (IV). Adult male mice lacking the uPA gene in C57BL/6J background (uPA-/-; B6.129S2-
Plautm1Mlg/J from The Jackson Laboratory, Bar Harbor, USA; Carmeliet et al., 1994) and their wild-
type (Wt) littermates were used in experiments (n=50). Mice were backcrossed to C57BL/6 genotype 
for at least 8 generations (The Jackson Laboratory). The genotypes of the mice were determined by 
PCR. Mice were housed in a controlled animal facility (as described for rats) with free access to food 
and water. 
4.2 Experimental animal models
4.2.1 SE induced with electrical stimulation of the amygdala (I, II, III)
Implantation of electrodes. Stimulation and recording electrodes were implanted as previously 
described by Nissinen et al. (2000). Briefly, anesthetized animals were placed into a stereotactic frame.
A bipolar stimulation electrode was implanted into the left lateral nucleus of amygdala [3.6 mm 
posterior and 5.0 mm lateral to the bregma, 6.5 mm ventral to the surface of the brain; according to the 
rat brain atlas of Paxinos and Watson (1989)]. A monopolar stainless steel screw electrode was 
implanted in the skull over the contralateral frontal cortex (3.0 mm anterior and 2.0 mm lateral to 
bregma). Two monopolar stainless steel screw electrodes placed over the cerebellum served as ground 
and reference electrodes. The electrodes were connected to a plastic pedestal (Plastics One Inc., 
Roanoke, VA) and fixed to the skull with dental acrylic (Selectaplus, Dentsply, DeTrey GmbH, 
Dreieich, Germany).
Induction of SE. Two weeks after the electrode implantation, SE was induced with electrical 
stimulation (20-30 minutes) of the lateral nucleus of amygdala via the intra-amygdaloid electrode 
(described in detail by Nissinen et al., 2000). The development of SE was monitored using the Nervus
EEG recording system connected to a Nervus magnus 32/8 Amplifier (Taugagreining, Reykjavik, 
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Iceland). The behavior of the animals was recorded with a video camera. Infrared light was used at 
night to allow video monitoring. To assure the animals had a sufficient severity of SE, the digitized 
EEG of each rat was analyzed visually on a computer screen and each high amplitude and frequency 
discharge (HAFD) was marked and counted [HAFD was defined as high amplitude (>2-fold baseline) 
and high frequency (>8 Hz) discharge in the amygdala, the cortex, or both, that lasted for at least 5 s].
The duration of SE was defined as the time between the first and the last HAFD. Only the animals that 
had more than 50 HAFDs were included in studies. Control animals had electrodes implanted but were 
not stimulated.
Continuous video-EEG monitoring. In order, to detect the occurrence of spontaneous seizures 
and to determine whether the animal was still undergoing epileptogenesis at the time of sacrifice (i.e., 
no spontaneous seizures) or was already epileptic, rats were monitored continuously with video-EEG 
(24 h/d) starting immediately after the induction of SE.  The system used for video-EEG monitoring 
has been described in detail by Nissinen et al. (2000). To detect the occurrence of seizures, digitized 
EEG of each rat was analyzed visually on the computer screen and seizures were marked. An 
electrographic seizure was defined as a high frequency (>5 Hz), high amplitude (>2-fold baseline) 
discharge either in the amygdala, the cortex, or both, that lasted for at least 5 s. Animals were divided 
into two groups according to the video-EEG data: epileptogenesis group (no spontaneous seizures) and 
epilepsy group (recurrent epileptic seizures). 
4.2.2 SE induced with intrahippocampal kainic acid injection (IV)
Induction of SE. Mice (age 9-12 weeks, n=50) were anesthetized and placed into a stereotaxic device. 
The skull was exposed and a small hole was drilled over the injection site (AP -2.0; ML 2.4 from 
bregma). Mice were then injected with 60 nl of 20 mM KA (K-2389; Sigma-Aldrich, St. Louis, USA; 
diluted in 0.9% NaCl) or 0.9% NaCl into the right hippocampus, just below the hippocampal fissure 
(AP -2.0; ML 2.4 with bregma as reference; DV 1.7 below dura; coordinates from the Mouse Atlas of 
Hof et al., 2000). The injection was performed using a glass capillar (outer diameter 0.75 mm; tip 
diameter 0.01-0.02 mm) connected to a pulse pressure device (Picospritzer; Science Products GmbH,
Hofheim, Germany). After injection, the capillary was kept in place for 5 min and then withdrawn 
slowly. After the operation, mice were injected with atipamezole hydrocloride (0.5 mg/kg i.p.; Orion 
Pharma, Espoo, Finland) and 0.9% saline (150 µl/animal) to facilitate awakening from anesthesia. 
Mice were kept on a heating pad until they had woken-up and then returned to their cages.
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4.3 Processing of the brain for histology
rats (amygdala stimulation)
Deeply anesthetized rats were transcardially perfused at 1 (n=4), 4 (n=5), or 14 d (n=7) after SE with 
0.9% NaCl (30 ml/min, +4oC, for 2 min), followed by 2% glutaraldehyde and 4% paraformaldehyde in 
0.1 M sodium phosphate buffer (PB), pH 7.4 (30 ml/min, +4oC, for 30 min). One or two control 
animals were perfused at each time point (n=4). After perfusion, the brains were quickly removed and 
postfixed for 4 h in the same fixative (4°C), cryoprotected in 20% glycerol in 0.02 M potassium 
phosphate buffered saline (KPBS, pH 7.4) for 36 h (4°C), frozen, and stored at -70°C until cut. The 
brains were cut into 4'.!coronal sections (1-in-6 series) in a sliding microtome. The first series 
of sections was stored in 10% formalin and used for Nissl staining. Other series were stored in a 
cryoprotectant tissue-collecting solution (30% ethylene glycol, 25% glycerol in 0.05 M PB) at -20°C 
until processed.
mice (intrahippocampal KA)
Six (n=24) or 20 d (n=22) after KA injection mice were deeply anesthetized and transcardially 
perfused with 0.9% NaCl (2 min) and 4% paraformaldehyde in 0.1 M PB (20 min). After perfusion,
the brains were removed from the skull, postfixed in 4% paraformaldehyde in 0.1 M PB at 4oC for 4 h, 
cryoprotected in 20% glycerol in 0.02 M KPBS at 4oC for 24 h, frozen on dry ice, and stored at -70oC. 
Coronal 25 µm thick frozen sections (1-in-6 series) were cut in a sliding microtome. The first series of 
sections was stored in 10% formalin and used for cresyl violet staining. Other series of sections were 
stored in cryoprotectant tissue collection solution.
4.4 Processing of the brain for cDNA arrays and PCR
For cDNA arrays and subsequent traditional RT-PCR, rats were decapitated with a guillotine at 1
(n=4), 4 (n=6) or 14 d (n=12) after SE. One or two control animals were perfused at each time point 
(n=5). The brains were quickly removed from the scull. Both hippocampi and temporal lobes
(amygdala, piriform and entorhinal cortices) were dissected from each rat, frozen, and stored at -70°C. 
Total RNA was extracted from the samples using Trisol Reagent (Sigma Chemical) according to the 
manufacturer’s instructions.
For real time qPCR (for uPAR), rats were deeply anesthetized and transcardially perfused at 1
(n=4), 2 (n=4), or 4 d (n=8) after SE with 0.9% NaCl (4 °C, 4 min). Two or five (4 d) control animals 
were perfused at each time point (n=9). After perfusion both hippocampi were quickly removed, frozen 
in liquid nitrogen in separate tubes, and stored at -70 °C.
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4.5 Processing of the brain for zymography 
For SDS-PAGE zymography, rats were decapitated with a guillotine 1 (n=5), 4 (n=6) or 14 d (n=7)
after SE, after which the brains were quickly removed. One or two control animals were perfused at 
each time point (n=5). Both temporal lobes (containing the amygdala, piriform, and entorhinal 
cortices) and hippocampi were dissected and used for protein extraction. The tissue was homogenized 
in 1 ml of extraction buffer that contained 1% Triton X-####)56$%'	#4/78'/
6'. &$$' 	# 4/78 '/ 6'.  $33&%3 &%' 	,)9 #
4/78'/6'.'#) Tris pH 7.5. The tissue homogenate was incubated for 15 min on 
ice and vortexed. subsequently, the homogenate was centrifuged 20 min in 10 000 rpm and supernatant 
was collected and stored in -70°C. 
4.6 cDNA array
For each cDNA array hybridization, equal amounts of RNA from two or three animals were pooled. 
cDNA probe was synthesized from 5 µg RNA using Strip-EZ™ cDNA Probe Synthesis and Removal 
Kit (Ambion, Inc., Austin, TX, USA) according to the manufacturer's instructions using 33P-dATP 
(NEN Life Science, Boston, MA, USA). Hybridization to GF300 filters containing 5000 rat gene 
probes (Research Genetics, Huntsville, AL, USA) was performed according to the protocols provided 
by the manufacturer. The imaging was performed by exposing the filters to phosphoimager screens 
overnight and then scanning the screens with Storm Phosphoimager (Molecular Dynamics, Sunnyvale, 
CA, USA). Filters were stripped using Strip-EZ™ cDNA Probe Synthesis and Removal Kit (Ambion) 
according to the manufacturer's instructions and used for the following hybridizations. Filters with a 
high or unequal background or with low signal intensity were excluded from the analysis. ArrayVision 
software (Imaging Research Inc., St. Catharines, Canada) was used for densitometric analysis of scans. 
Probes obtained from control, 1-, 4- and 14-d epileptogenesis and 14-d epilepsy groups were 
sequentially hybridized to the filters in a random order (Experiment I). The experiment was repeated 
using separate groups of animals, separate RNA extraction, and separate filters (Experiment II).
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4.7 PCR
4.7.1 Semiquantitative Multiplex RT-PCR. 
Semiquantitative RT-PCR was performed using mRNA that was obtained from the temporal lobes 
(containing the amygdala, piriform, and entorhinal cortices) and hippocampus of animals sacrificed 1, 
4 or 14 d after SE (n=4 each group). Reverse transcriptase reaction was performed according to the 
following protocol: 6 µg RNA was incubated with 4 l of DNAse I (1 U/l; Amplification Grade; Life 
Technologies, in a total volume of 20 l for 15 min. Subsequently, 2 l of EDTA (25 mM) was added 
and the sample was heated for 15 min at 65°C. The reverse transcription reaction was performed in a 
total volume of 50 l, containing 2 %:%;2	#<4/748,%/)'%=>+
5 l dNTPs (20 mM each; Promega), 1  :5' 	# +748 ,%/  l M-MuLV Reverse 
Transcriptase (200 U/l; New England Biolabs, Beverly, MA), and 1x M-MuLV Buffer. Following 30 
min incubation at 37°C, the volume was adjusted to 200 l and aliquots were used for PCR. The PCR 
reaction was performed in a total volume of 25 l containing 2.5 l of cDNA, 1.5 mM MgCl2, 0.2 mM 
dNTP, 0.2 M primer, and 0.25 l of Taq Polymerase (5 U/l; Life Technologies or Finnzymes, 
Espoo, Finland) and 2 l of 18S primers (Quantum RNATM Internal Standards, Ambion) that were 
used as an internal standard. The hot-start protocol was employed with the aid of DyNAwax 
(Finnzymes). The reaction was run in a thermal cycler (MJ, Research Inc., Cambridge, MA, USA) 
using the following program: 94°C, 30 s; 58°C, 1 min; 72°C, 1 min. The number of PCR cycles was 
determined by removing aliquots after every third cycle.  A cycle within the exponential range of 
amplification was used for subsequent study.  The amplification of the internal control 18S (Quantum 
RNATM Internal Standards, Ambion) was adjusted for each reaction according to manufacturer’s 
instructions. PCR products were resolved on a 1.5% agarose gel and stained with CyberGreen 
(Molecular Probes, Eugene, OR, USA). The images were captured using Storm Phosphoimager and 
analyzed using ImageQuaNTTM 4.1 (Molecular Dynamics). In order to calculate the level of 
expression, the optical density of specific gene product was divided by optical density of an 18S 
product and to control the purity of PCR reactions, three controls were used: 1) reaction with no 
cDNA, 2) reaction without 18S primers, 3) reaction without studied gene primers. The primers that 
were used in the study: for biglycan, 5'-GGCCTACTATAATGGCATCAGC-3' and 5'-
AGAGCCCAGGAGAGCTAGAAGT-3'; for cathepsin S, 5'-CGTCTCATCTGGGAAAAGAATC-3' 
and 5'-GACACTTTTCATCCATGGCTTT-3'; for uPA: 5'-AGGTCTGCTGTTGGGAAATAAA-3' and 
5'-GTGAGGATTGGATGAACTAGGC-3'; expressed sequence tags (ESTs), highly similar to LAS1: 
5'- TCCAGGGAACATTTCATTTCCTA-3' and 5'- TCACTTTGTGGTTCAAGTCAATG-3'.
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4.7.2 Real time qPCR
Real time qPCR was performed to study the expression of uPAR in rat hippocampal samples obtained 
1, 2 or 4 d after SE. Total RNA from the left hippocampus of rats was isolated using TRI Reagent® 
RT Kit (# RT 111, Molecular Research Center, Inc., Cincinnati, OH, USA) using the manufacturer’s 
protocol. In order to remove traces of DNA, 10 µg of RNA was incubated with 2 µl DNase I (1 U/µl, # 
EN0521, Fermentas, Burlington, Canada) in 1 µl reaction buffer (Fermentas) for 30 min at 37 °C. 
DNase inactivation was performed by adding 5 µl 25 mM EDTA (Fermentas) and incubating the 
samples for 10 min at 65 °C. The absence of genomic DNA in the RNA samples was verified by 
per%'/,6:$''.'% '-actin primers (5´-ACCTTCCAACACCCCAGCCAT-3´ and 5´-
TCACGCACGATTTCCCTCTC-3´; Oligomer, Helsinki, Finland). The PCR reaction was performed 
in a total volume of 30 µl and the reaction contained dilute RNA (1:25), primers (10 pmol/µl), 0.3 µl 
dNTPs (10 mM each; Finnzymes), 0.4 µl DyNAzyme II DNA polymerase (2 U/µl, Finnzymes) and 1µ 
buffer for DyNAzyme DNA polymerase (Finnzymes). The PCR reaction was run in a PTC-100 
Programmable Thermal Controller (MJ Research Inc.) using 35 cycles with the following program: 95 
°C, 20 s; 58 °C, 20 s; 72 °C, 20 s. PCR products were then run on an agarose gel. After the purity of 
samples was confirmed, the total RNA was transcribed to cDNA using High Capacity RNA-to-cDNA 
Kit (#4387406, Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s protocol. 
Quantitative RT-PCR reactions were performed in a total volume of 20 µl using 12 ng (RNA 
equivalents) of cDNA as template, gene-specific primers (pre-validated TaqMan Gene Expression 
Assay for uPAR, ID: Rn00569290-M1, Applied Biosystems) and probe (pre-validated TaqMan Gene 
Expression Assay; ID: Rn00569290-M1, Applied Biosystems) and 1µl TaqMan Gene Expression 
Master Mix (# 4369016, Applied Biosystems). The qPCR reaction was run in ABI BRISM 7700 
(Applied Biosystems) using the following program: 2 min at 50 °C, 10 min at 95 °C, and 40 cycles of 
15 s at 95 °C and 1 min at 60 °C. Data were normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) mRNA expression (pre-validated TaqMan Gene Expression Assay for GAPDH; ID: 
Rn99999916-s1, Applied Biosystems).
4.8 SDS-PAGE zymography
In the SDS-PAGE zymography, e?& %& % $%' 2. 	# 4/   '2  '
nonreducing SDS-PAGE sample buffer and run in a 10% SDS-PAGE gel containing 0.1% casein 
(Sigma Chemical) and 11 mU/ml plasminogen (Roche Biochemicals, Mannheim, Germany). After 
electrophoresis, the gel was washed with 2.5% TX-100 solution and then with 0.1 M Tris pH 8.0. The 
gel was incubated 18 h in 0.1 M Tris pH 8.0 at +37°C to allow proteolysis to occur and then stained 
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with Coomassie brilliant blue (Sigma Chemical). Excess stain was removed with a solution containing 
35% methanol, 7% acetic acid. uPA and tPA activity could be then observed in the gel as light bands 
against a dark background. Control gels were incubated with uPA inhibitor amiloride (0.4 mM; Sigma 
Chemical) in 0.1 M Tris pH 8.0. Plasminogen was omitted from the gel, in the negative controls. The 
gel image was captured with a GS-710 densitometer (Bio-Rad, Hercules, CA, USA) and band 
intensities were measured using ImageQuant program (Bio-Rad).  
4.9 Histology and immunohistochemistry
4.9.1 Nissl staining
The first series of brain sections of each animal was used for Nissl staining with cresyl violet. Sections 
were washed carefully with 0.1 M PB, mounted on gelatin coated slides, and dried. The slides were 
then stained using the following protocol: 3 min in 0.125% cresyl fast violet solution, 2 times 1 min 
dH2O, 2 min 50% ethanol, 2 min 70% ethanol, 2 min in differentiation solution (25% chloroform, 
0.06% acetic acid in 96% ethanol), 2 min 95% ethanol, 2 times 1 min in absolute ethanol, 3 times 3
minutes in xylene. Finally slides were coverslipped using DePeX (BDH Chemical, Poole, United 
Kingdom) as mounting medium. 
4.9.2 Fluoro-Jade B
Fluoro-Jade B staining for detection of degenerating cells was done according to Schmued et al. 
(1997). Briefly, sections were washed three times 10 min with phosphate buffer, mounted on glass 
slides, and dried overnight at +37°C. Slides were rehydrated in absolute ethanol (3 min), 70% ethanol 
(2 min), and dH2O (2 min). Then, the slides were incubated in 0.06% potassium permanganate for 15 
min, rinsed in dH2O (2 min) and incubated for 30 min in a solution containing 0.001% Fluoro-Jade B 
(Histo-Chem Inc., Jefferson, AR) and 0.1% acetic acid. The sections were washed briefly with dH2O, 
dried, and dehydrated in series of xylene and coverslipped. Images were captured with a fluorescence 
microscope.
4.9.3 uPA immunohistochemistry
In the uPA immunohistochemistry, free-floating brain sections were washed in 0.05 M Tris-buffered 
saline (TBS, pH 7.4). Endogenous peroxidase activity was removed by incubating the sections for 15 
min in 1% H2O2 in 0.05 M TBS. In order to increase antibody penetration, sections were treated with 
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1% sodium-borohydride for 15 min and washed with TBS. To block non-specific binding, sections 
were incubated for 2 h in a solution containing 10% normal horse serum (NHS) and 0.5% Triton X-
100 (TX-100) in TBS.  Thereafter, sections were incubated for 2 d in a solution containing goat-
polyclonal antibody raised against uPA (1:700; sc-6831; Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA, USA), 1% NHS, and 0.5% TX-100 in 0.05 M TBS at 4oC. Sections were washed and then 
incubated overnight in a solution of biotinylated rabbit anti-goat IgG (1:200, BA-5000; Vector 
Laboratories, Burlingame, CA, USA), 1% NHS, and 0.5% TX-100 in 0.05 M TBS at 4C. Sections 
were washed with TBS and moved to 1% avidin-biotin (PK4000; Vector Laboratories) solution for 1 h. 
After washing, the sections were recycled back to the secondary antibody solution for 45 min, and then 
to avidin-biotin solution for 30 min. The secondary antibody was visualized with 0.05% 3',3'-
diaminobenzidine (DAB, Pierce Chemical, Rockford, IL, USA) and 0.04 % H2O2 in TBS. Finally, 
sections were washed with TBS, moved to PB solution, and mounted on gelatin-coated microscope
slides. Slides were dried overnight at 37C and then the reaction product was intensified with to 
osmium (OsO4) - thiocarbohydrazide according to the method of Lewis et al. (1986). 
Specificity of immunostaining was tested by two methods. First, omitting of the primary antibody 
resulted in the disappearance of all immunostaining. Second, preabsorption of primary antibody 
overnight (4°C) with specific blocking peptide (concentration range 1-200µg/ml, sc-6831P, Santa Cruz 
Biotechnology) resulted in disappearance of the uPA immunoreactivity in a concentration dependent 
manner. Only the labeling in the infrapyramidal blade of the granule cell layer could not be totally 
blocked with the preabsorption test and thus it was considered to be non-specific labeling. 
4.9.4 uPAR immunohistochemistry
For uPAR immunohistochemistry, similar protocol was used as for uPA. The primary antibody used 
was goat-polyclonal antibody raised against uPAR (1:500; sc-9795; Santa Cruz Biotechnology) and 
secondary was biotinylated rabbit anti-goat IgG (1:200, BA-5000; Vector Laboratories).
Immunostaining specificity was tested by several methods. First, omitting the primary antibody 
resulted in the disappearance of all immunostaining. Second, preabsorption of primary antibody 
overnight (4°C) with specific blocking peptide (concentration range 1-40 µg/ml, sc-9795P, Santa Cruz 
Biotechnology) resulted in disappearance of the uPAR immunoreactivity in a concentration dependent 
manner. Third, a few sections were stained with another antibody, polyclonal goat anti-mouse uPAR-1
(AF534, R&D Systems), and the pattern of immunoreactivity was found to be similar to that observed 
with sc-9795 (Santa Cruz) antibody. Furthermore, AF535 was shown to specifically recognize rat 
uPAR on western blot in samples obtained from HEK 293T cells transduced with rat uPAR.
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4.9.5 Double immunohistochemistry for confocal microscopy
uPA double immunohistochemistry
In the double-immunohistochemistry with neuronal (NeuN), astrocytic (GFAP), microglial (ILB4), 
radial glial (3CB2; later identified as vimentin by Pérez-Álvarez et al., 2008), or endothelial 
(SMI71/EBA) markers, sections were first rinsed with 0.05 M TBS  and incubated for 15 min in  1% 
sodium-borohydride solution. After washing, non-specific binding was blocked by incubating the 
sections in 10% NHS and 0.5 % TX-100 in TBS for 40 min. Sections were then washed for 15 min in a 
solution containing 1% NHS and 0.5% TX-100 in TBS. The sections were incubated in primary 
antibody solution containing goat anti-uPA antibody (1:700; sc-6831; Santa Cruz Biotechnology) and 
mouse anti-neuronal nuclei antibody (NeuN, 1:10000; Chemicon, Temecula, CA, USA) or mouse anti-
glial fibrillary acidic protein antibody (GFAP, 1:4000; Boehringer Mannheim, Germany) or FITC 
labeled isolectin B4 (ILB4, <4/78 '/6'. < @%&')A+%%& '-3CB2 
antibody  (1:100; Developmental studies hybridoma bank, University of Iowa, Department of 
Biological Sciences, Iowa City, IA, USA) or mouse anti-endothelial barrier antigen (EBA, 1:10000; 
Sternberger Monoclonals Inc., Lutherville, MD, USA) that were dissolved in 1% NHS and 0.5% TX-
100 in TBS for 2 d at 4C. Before secondary antibody incubation, the sections were washed in solution 
containing 1% NHS and 0.5% TX-100 in TBS. Sections were then incubated overnight (4°C) in a 
secondary antibody solution containing biotinylated rabbit anti-goat (1:200; Vector Laboratories), 
Alexa 488 conjugated anti-mouse IgG (1:500; Molecular Probes, Leiden, The Netherlands), 1% NHS, 
and 0.5% TX-100 in TBS. Sections were then washed with 1% NHS in TBS and incubated for 3 h in 
Cy5-.%B&/$1''	4/7C.!%>&%.=Dove, PA, USA), 1% NHS in 
TBS. Sections were washed with 0.05 M Tris (pH 7.4) and rinsed with dH2O. The sections were 
mounted on glass microscope slides, dried, and coverslipped using Vectashield (Vector Laboratories). 
Images were captured with a Nikon laser-scanning confocal microscope (Nikon GmbH, Düsseldorf, 
Germany) equipped with Ultra View LCI confocal imaging system (Perkin Elmer, Fremont, CA) using 
excitation/emission wavelengths of 488/525 nm for Alexa 488 and 647/700 nm for Cy5.
uPAR double immunohistochemistry
The protocol used to perform double-staining with uPAR and neuronal (NeuN), astrocytic (GFAP), 
microglial (ILB4), parvalbumin (PARV), somatostatin (SOM), calretinin (CR), calbindin (CB), and 
neuropeptide Y (NPY) markers, was similar to the uPA double-staining described above. Primary 
antibody reaction included: goat anti-uPAR antibody (1:500; sc-9795; Santa Cruz Biotechnology) and 
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mouse anti-neuronal nuclei antibody (NeuN, 1:10000; Chemicon) or mouse anti-glial fibrillary acidic 
protein antibody (GFAP, 1:4000; Boehringer Mannheim) or FITC labeled isolectin B4 (ILB4, 5.5 
4/78 '/6'.) or mouse anti-PARV (1:10000; Swant, Bellinzona, Switzerland) or mouse 
anti-CB (1:30000; Swant) or rabbit anti-SOM (1:400; Chemicon) or rabbit anti-CR (1:9000; Swant) or 
rabbit anti-NPY (1:10000; Peninsula Laboratories, San Carlos, CA, USA). Secondary antibody 
reaction: biotinylated rabbit anti-goat (1:200; Vector Laboratories, secondary antibody for uPAR) and 
Alexa 488 conjugated anti-mouse IgG (1:500; Molecular Probes, Leiden, The Netherlands) (Secondary 
antibodies NeuN, GFAP and PARV antibodies) or biotinylated horse anti-goat (1:200; Vector 
Laboratories, secondary antibody for uPAR) and Alexa 488 conjugated chicken anti-rabbit IgG (1:500, 
Molecular Probes) (Secondary antibodies for SOM, CR and NPY antibodies). Images were captured 
with the same equipment as described for uPA stainings using excitation/emission wavelengths of 
488/525 nm for Alexa 488 and FITC and 647/700 nm for Cy5.
4.9.6 Doublecortin immunohistochemistry
For detection of neurogenesis, doublecortin (DCX) immunohistochemistry was performed. Sections 
were first carefully with 0.02 M KPBS and incubated for 15 min in 1% H2O2 in KPBS to remove 
endogenous peroxidase activity. Sections were rinsed with KPBS and non-specific binding was 
blocked by incubating the sections in a solution containing 10% NHS, 0.4 % Triton X-100, and KPBS 
at RT for 2 h. This was followed by overnight incubation at 4°C with goat anti-doublecortin (1:800; 
SC-8066; Santa Cruz Biotechnology) in 1% NHS and 0.4% Triton X-100 in KPBS. Sections were 
washed with KPBS and incubated for 2 h in a secondary antibody solution containing biotinylated 
horse anti-goat IgG (1:300; BA-9500; Vector laboratories), 1% NHS, and 0.4% Triton X-100 in KPBS. 
Sections were washed with KPBS and moved to 1% avidin-biotin (PK-4000; Vector Laboratories) in 
KPBS for 1 h. After washing, the sections were recycled back to the secondary antibody solution for 
45 min, and then to avidin-biotin solution for 30 min. The secondary antibody was visualized with 
DAB (Pierce Chemical). Finally, sections were washed with 0.1 M PB, and mounted on gelatin-coated 
microscope slides. Slides were dried overnight at 37C and coverslipped.
4.10 Data analysis
4.10.1 Gene expression
cDNA arrays (I). Data were analyzed using GeneSpring software (Silicon Genetics, Redwood City, 
CA, USA). To determine changes in gene expression, the optical density ratios of 1, 4 and 14-day 
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epileptogenesis and 14-day epilepsy groups relative to controls were calculated using data obtained 
from the same filter (note that Experiments I and II were performed on different filters). Normalization 
was performed using the options provided by software: distribution of all genes for per chip 
normalization and Lowess fit for per spot intensity-dependent normalization. Normalized values below 
0 were set to 0. Candidate epileptogenesis or epilepsy-related genes were selected by applying strict 
criteria: (1) intensity of the spot E< × background value; (2) gene had to be expressed at detectable 
levels (E< × background value) in both experiments in at least two time points, and (3) expression 
ratio relative to controls had to be F#<
%E<" '0% $'. 2$' at a given time point. 
Critena limits were set according to previous experiments where the number of true positive findings 
was tested with RT-PCR (unpublished).
4.10.2 Neuronal damage in the hippocampus
Severity of degeneration of hippocampal pyramidal neurons in the CA1 and CA3 subfields was 
analyzed bilaterally from cresyl violet stained sections and scored according to Freund et al. (1992) as 
follows: 0 = no cell loss, 1 = less than 20% of neurons lost, 2 = 20 to 50% of neurons lost, 3 = over 
50% of neurons lost. Eight consecutive sections starting from the level at which the suprapyramidal 
and infrapyramidal blades of the granule cell layer become fused together (atlas coordinate -1.3 mm 
from bregma) were analyzed blinded to the experimental group. The severity of neurodegeneration in 
each subfield in each section was scored, and the mean score was used for statistical analysis.
The total number of hilar cells was estimated in the ipsilateral and contralateral hippocampus using 
unbiased stereology. Systematic sampling of sections with a random start, covering the entire 
septotemporal axis of the hippocampus was employed. Every second section (8-9 sections per animal) 
beginning at -1.10 mm caudal to bregma were sampled. Sections were analyzed using 
StereoInvestigator software (Version 2006, MicroBrightField Inc., Colchester VT, Germany) under 
an Olympus BX50 microscope equipped with a motorized stage and a Hitachi HV-C20A camera. The 
total number of hilar cells was estimated using the optical fractionator method (West et al., 1991). This
 %03$.'/$'//'%#4	2-2'#4	3-axis) on the section. For each x–y
step, cell counts were derived from a known fraction of 4	2-2'034	3-axis). Counting 
was performed throughout the section, avoiding the neurons that were in focus at the surface of the 
section. Neuronal nuclei were counted only as they first came into focus within each optical dissector. 
Glia were excluded from the counts. The total number of hilar cells was calculated with following 
equation: NtotGHI×1/ssf ×1/asf ×1/tsf , where section sampling fraction (ssf) is 1/12, area sampling 
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fraction (asf, the area of counting frame divided by area of sampling grid) 0.49, and tissue sampling 
fraction (tsf, the height of the mounted section thickness divided by the dissector height) is 1.
4.10.3 Granule cell dispersion
The effect of genotype on GCD was studies by measuring the volume of the granule cell layer 
bilaterally using Cavalieri’s principle. The same section sampling scheme was used as described 
above. A gr'%##4	2-2'03##4	3-axis) was laid on the section. Thus, the area per hit 
point [a(p)] was 0.01 mm2. The total number of hit points within the selected area of interest was 
counted as described by Gundersen and Jensen (1987). The volume of the granule cell layer was 
calculated using the formula: V = J,i . a(p) . T, where Pi is the total number of hit points counted in all 
sections, a(p) is the area associated per point (0.01 mm2), and T is the section thickness (##4).
4.10.4 Analysis of immunohistochemically stained brain sections
4.10.4.1 uPA
uPA immunoreactivity was semiquantitatively scored in hippocampal areas CA1 (s. oriens, s.  
pyramidale, s. radiatum, s. lacunosum-moleculare), CA3 (s. oriens, s.  pyramidale, s. radiatum)  and 
dentate gyrus (molecular layer outer and mid third, molecular layer inner third, hilus) as follows:KG
not present, + = light, ++ = moderate, +++ = heavy. Scoring was done blinded to the experimental 
group. The mean score was calculated for each brain area studied in each group. Notes of the cellular 
appearance of immunolabeled cells were also taken.
In order to determine the identity of cells expressing uPA in the rat hippocampus and corpus 
callosum, double-immunohistochemistry with neuronal (NeuN), astrocytic (GFAP), microglial (ILB4)
and radial glia (3CB2) markers was performed. Since the regular immunohistochemistry suggested that 
some of the positive elements could be blood vessels, double-immunohistochemistry was also 
performed with an antibody raised against EBA that labels rat endothelial protein found in areas of 
blood-brain barrier or blood-nerve barriers. Two double-stained sections from each timepoint were 
studied with a laser-scanning confocal microscope.
4.10.4.2 uPAR
uPAR immunoreactivity was semiquantitative scored as described for uPA. To determine the identity 
of cells expressing uPAR in the rat hippocampus, double-immunohistochemistry with neuronal 
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(NeuN), astrocytic (GFAP), microglial (ILB4) and radial glia (3CB2) markers was performed similarly 
to uPA double-stainings. In addition, double-stainings were performed with parvalbumin (PARV), 
somatostatin (SOM), calretinin (CR), calbindin (CB), and neuropeptide Y (NPY) markers. Double-
stained cells were counted from two double-stained sections from control and 4 d SE group using a
confocal microscope. 
4.10.4.3 Doublecortin
Doublecortin stained mouse brain sections were used to assess the effect of genotype on number and 
migration of newly born granule cells in the hippocampus at 20 d after KA injection. As no DCX-
positive cells were present in the ipsilateral side, only the contralateral side was analyzed. In order to
assess migration, the DCX-positive cells were counted separately in the hilus, in the subgranular zone, 
and in the granule cell layer by using stereology. Sampling of sections was performed as described for 
measuring the granule cell layer dispersion. Using the optical fractionator method, the area of interest 
was outlined at low magnification. Thereafter, 1'&$'//'%#4	2-2'03#4	3-
2' '%.'%<.%&'/ ' '%<"4	2-axis) and a height of 18.72 
4	3-axis) was used in counting the cells.  The following formula was used in estimating the total 
number of DCX positive cells in these areas: NtotGHI×1/ssf ×1/asf ×1/tsf, where ssf is 1/12, asf is 0.23 
and tsf is 1.
4.10.5 Statistics
Data were analyzed using SPSS for Windows (versions 11.0-16.0). Differences between groups were 
analyzed using the Kruskall–Wallis test and post hoc analysis using the Mann–Whitney U test (I, II,
III, IV). Differences between brain hemispheres were analyzed with the Wilcoxon signed rank test
(IV). Differences between the groups following non-parametric scoring were analyzed using chi-
square test (IV). Data are presented as mean± standard deviation (SD) or standard error of the mean 
(SEM). A p-value less than 0.05 was considered significant. A statistician was consulted in the 
selection of the appropriate tests (IV).
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5. RESULTS
5.1 Gene-expression changes during epileptogenesis and epilepsy (I)
The gene expression during epileptogenesis and epilepsy was studied 1, 4 and 14 d after SE. When 
RNA was hybridized to a cDNA array that contained 5000 gene probes, 282 genes were found to 
change their expression during epileptogenesis or epilepsy in the hippocampus or the temporal lobe at 
least at one time point (I, Fig. 1).
In the hippocampal samples, 1700 genes showed expression at least 2.5-fold compared to the 
background level in two experiments and these genes were included in the analysis. Eighty-seven 
genes displayed an experimental: control expression ratio of F#<
%E<"'$%''
two experiments and these were considered as candidate epileptogenesis/epilepsy-related genes (I, 
Fig. 1A). The 87 genes included 32 known genes, 16 expressed sequence tags (ESTs) with homology 
to known genes, and 39 ESTs with no homology to known genes. In the 1-day group, eight genes were 
down-regulated and 29 were up-regulated. In the 4-day group, 2 genes were down-regulated and 10 
were up-regulated. In 14-day epileptogenesis group, 11 genes were down-regulated and three were up-
regulated. In the 14-day epilepsy group, 30 genes were down-regulated and 12 were up-regulated (I, 
Fig. 1A). No gene was up- or downregulated at more than one timepoint during epileptogenesis.
However, the same four genes were down-regulated both in the 14-day epileptogenesis group and in 
the 14-day epilepsy group (I, Fig. 3B).
In the temporal lobe samples, 1786 genes showed expression which was at least 2.5-fold different 
from the background level in two experiments and were included in the analysis. A total of 208 genes 
displayed an experimental: control expression ratio of F#<
 % E<"   % ' $%' ' 0%
experiments and were considered to be candidate epileptogenesis/epilepsy-related genes (I, Fig. 1B). 
These 208 genes included 69 known genes, 45 ESTs with homology to known genes and 94 ESTs with 
no homology to any known genes. In the 1-day group, 13 genes were down-regulated and 16 were up-
regulated. In the 4 d group, 98 genes were down-regulated and 57 were up-regulated. In the 14 d
epileptogenesis group, 15 genes were down-regulated and 17 were up-regulated. In the 14 d epilepsy 
group, four genes were down-regulated and 58 were up-regulated (I, Fig. 1B). In the temporal lobe, six
genes were similarly altered at all three time points during epileptogenesis (I, Fig., 3A). Two of these 
genes were down-regulated and four were up-regulated. In both the 1 d and 4 d groups (five down- and 
nine up-regulated), 14 genes were similarly altered: three in the 1-day and 14-day epileptogenesis 
groups (all down-regulated), and nine in the 4 d and 14 d epileptogenesis groups (five down- and four 
up-regulated). Nine genes were similarly upregulated in 14 d epileptogenesis and epilepsy groups (I, 
Fig. 3B).
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With respect to the candidate epileptogenesis/epilepsy-related genes, 13 were common to both the 
hippocampus and the temporal lobe and only four genes displayed changes in the same direction at the 
same time point in both brain areas. Three of the genes were up-regulated at 4 days and one at 14 d. 
In order to assess the reliability of cDNA array results, RT-PCR was performed for four genes that 
were found upregulated in the cDNA array experiments. Upregulation of three (cathepsin S, biglycan 
and uPA) out of four genes were confirmed to be upregulated in the extrahippocampal temporal lobe
samples. Especially, uPA gene expression was clearly upregulated in animals which had experienced
SE (I, Fig. 2). 
5.2 Expression of uPA in the rat brain (I, II)
Control rat hippocampus
According to RT-PCR and immunohistochemistry, the expression of uPA protein in the normal rat 
brain was low. A very consistent uPA labeling in the infrapyramidal blade of the granule cell layer of 
the dentate gyrus was observed in control rats. However, this was considered to be unspecific staining 
as it could not be totally deleted in the preabsorption test. Scattered lightly labeled uPA positive 
elements with glial appearance were present in the hilus and the molecular layer (II, Fig.1, panel A1) 
as well as in all hippocampal subfields and layers (II, Fig. 1, panels B1, C1). Colocalization of uPA 
with GFAP in double-staining preparations confirmed that the cells with glial appearance were 
astrocytes and showed that uPA was localized to astrocyte somata (II, Fig. 3A). Pronounced
immunoreactivity was observed in pyramidal cells, glia, and neuropil in hippocampal regions 
(typically CA1, distal CA3) that were traumatized by the stimulation electrode penetrating the brain. 
We did not find uPA immunoreactivity in microglial cells in control animal hippocampus.
Epileptogenic rat hippocampus
The tempo-spatial expression of uPA protein in the rat brain was investigated at 1, 4 and 14 d after SE. 
According to the array and PCR data, uPA mRNA expression was upregulated in rat temporal lobe 1-
14 d after SE (I). However, immunohistochemical analysis of the extrahippocampal temporal lobe 
could not be performed due to the extensive damage in these areas. Thus, only the hippocampal 
expression of uPA was studied in detail. 
A robust increase in the number and intensity of uPA-immunoreactive elements was observed in 
animals that had experienced SE 1 d prior to sacrifice (II; Table 1; Fig. 1, panels A2, B2, C2). All 
layers of the hippocampus proper showed increased uPA-immunoreactivity in cells with glial 
appearance. In particular, the stratum lacunosum moleculare (II, Fig.1, panel C2) was occupied with a
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large number of immunopositive elements with glial morphology. Double-stainings confirmed that the 
observed glial cells were astrocytes. In addition, the majority of the cells in the pyramidal cell layer in 
the CA3-CA1 subfields were heavily labeled throughout the septotemporal axis of the hippocampus.
Double-staining with NeuN confirmed that these cells were neurons (II, Fig. 3D). Neuropil labeling 
was intense throughout the hippocampal layers, however, Stratum lucidum in CA3 remained 
unstained. The intensity of uPA immunostaining correlated with the density of degenerating neurons in 
adjacent sections stained with Fluoro-Jade B (II, Fig. 4). In the dentate gyrus, a consistent increase in 
immunoreactivity was observed (II, Table 1; Fig 1, panel A2). Intensively labeled immunopositive 
cells were located in the infragranular region as well as at the border between the inner and mid 
molecular layers, and between the mid and outer molecular layers (II, Fig. 1, panel A2; Fig. 2E). 
Further, many of the immunopositive cells emanated long vertically oriented processes through the 
molecular layer (II, Fig. 2D). Double-labeling experiments indicated that these cells were astrocytes 
and this demonstrated that uPA-immunoreactivity is found both in astrocytic somata and processes as 
well as lining the outer surface of the astrocytic processes (II, Fig. 3B). In addition, the hippocampal 
fissure contained an intensely labeled chain of immunopositive astrocytes. All uPA expressing cells 
with a glial appearance expressed also radial glia marker, 3CB2 (II, Fig. 3C) but no colocalization with 
microglia was found. Inner molecular layer showed intense neuropil labeling throughout the 
septotemporal axis (Fig. 2D).
In the 4-d group, strong uPA immunoreactivity of astrocytes in the entire hippocampus persisted. A
large number of the principal cells of hippocampus proper displayed uPA expression (II, Fig.1, panels 
B3, C3). The staining however appeared more diffuse and was not confined strictly to neuronal somata 
as at 1 d after SE (II, see Fig. 1, B2 and B3). Double-labeling with NeuN showed uPA positivity also 
in the neuropil around uPA immunopositive pyramidal cells. Fluoro-Jade B staining confirmed that the 
increased uPA immunoreactivity localized with degenerating neurons (II, Fig. 4). The intensity of 
neuropil staining in the stratum oriens and radiatum in the CA3 and CA1 subfields was even more 
intense that at 1 d (II, Fig. 1, panels B3 and C3). In the dentate gyrus, the staining at 4 d after SE 
resembled that observed at 1 d after SE, however the Xertically orientated astrocytes in the outer 
molecular layer were more intensely labeled than at 1 d timepoint.The inner molecular layer exhibited
very intense neuropil staining (II, Fig. 1, A3).
In the 14-d epileptogenesis group, the intensity of immunoreactivity decreased compared to 4 d, but
a large number of uPA immunopositive principal cells were still visible in the CA3a region as well as 
in the CA1, particularly at the lesion site (II, see Fig. 1, panel C4). A large number of uPA positive 
astrocytes were present in the stratum radiatum of the CA1. Neuropil labeling was most intense in 
stratum oriens and radiatum of the CA1. In the dentate gyrus, the intensity of uPA immunolabeling
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was decreased compared with that observed in the 1- and 4-d groups (II, Fig. 1, A4). Further, 
immunostaining in the hippocampal fissure was no longer present. Both the number and intensity in 
the labeling of astrocytes in the molecular layer was also substantially reduced.
Epileptic rat hippocampus
Comparison of uPA immunoreactivity between 14 d epileptogenesis and epilepsy groups revealed no 
major differences in the hippocampal expression of uPA.
5.3 Activity of uPA and tPA in the rat hippocampus and temporal lobe (II)
uPA. The activity of uPA was studied 1, 4 and 14 d after SE from samples collected from the 
hippocampus and temporal lobe. According to SDS-PAGE zymography, the activity of uPA was low 
in the normal rat brain both in the hippocampus and extrahippocampal temporal lobe. One day after 
SE, uPA activity in the hippocampus had increased 4,8-fold (P<0.05, II, Fig. 5A) compared to control 
animals. At 4 d and 14 d, uPA activity attenuated compared to 1 d after SE values but remained 
elevated (2.4-fold and 2.9-fold, both p<0.05; II, Fig. 5A) compared to control animals. In the 
extrahippocampal temporal lobe, uPA activity had increased up to 7.5-fold (P<0.05) at 1 d after SE and 
stayed elevated throughout the entire 2-wk follow-up (II, Fig. 5B).
tPA. tPA activity was also measured from the same samples used to uPA activity measurements. 
Prominent tPA activity was present in the hippocampus and extrahippocampal temporal lobe of control 
animal (II, Fig. 5C and 5D). At 1 d after SE, enzymatic activity of tPA in the hippocampus and the 
extrahippocampal temporal lobe had declined to 50% of that in controls (both p<0.05). At the 4d and 
14d timepoints, the tPA activity was comparable to the tPA activity measured from control animals.
5.4 Expression of uPAR in the rat hippocampus (III)
Expression of uPAR in normal rat hippocampus
According to real time qPCR and immunohistochemical analysis, the hippocampal expression of 
uPAR was low in control rats. In the hippocampus proper, lightly stained glial cells were present in all 
layers of the CA1 (III, Fig. 2, C1) and CA3 (III, Fig. 2, D1). Double-staining experiments indicated
that these cells were astrocytes. Occasional lightly stained uPAR positive neurons were observed in the 
stratum oriens (CA1) and stratum pyramidale (CA1 and CA3). Light neuropil staining was observed in 
the stratum pyramidale. In the dentate gyrus, the expression of uPAR confined mostly in astrocytes in 
the molecular layer and hilus (III, Fig. 2, A1 and B1). Occasional large uPAR-positive neurons were 
observed within the granule cell layer (III, Fig.2, B1), in the supragranular region, and in the inner 
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molecular layer. Some immunopositive neurons were also present in the hilus, particularly in the 
infragranular region. Increased uPAR immunoreactivity was observed in glia, neurons (in the 
hippocampus), and neuropil in areas adjacent or traversed by the stimulation electrode.  
Expression of uPAR in epileptogenic rat hippocampus
According to qPCR, 1 d after SE the expression of uPAR mRNA was increased 25-fold compared to 
control rats (p<0.05; III, Fig. 3). Immunohistochemical staining revealed that the density of uPAR 
positive elements increased dramatically after SE (III, Table1; Fig.2, panels A2, B2, C2, D2). In the 
hippocampus proper, the density of heavily labeled uPAR positive astrocytes increased in the stratum 
radiatum (CA1 and CA3) and at the border region between the stratum radiatum and stratum 
lacunosum-moleculare (CA1) as compared to controls (III, Fig. 2, C2, D2). Notably, the number of 
intensely labeled uPAR positive neurons increased in the stratum oriens and pyramidale at CA1 (III, 
Fig. 2, C2) and CA3 (III, Fig. 2, D2). Further, the intensity of neuropil labeling increased substantially 
in the CA1 area at the border region between stratum radiatum and lacunosum-moleculare (see III, 
Fig. 2, C2) and in all layers or CA3. In the dentate gyrus, the density of uPAR positive astrocytes 
increased dramatically in the molecular layer (III; Table 1; Fig. 2, A2 and B2). Interestingly, many of 
the uPAR immunopositive astrocytes were oriented in a perpendicular direction to the granule cell 
layer and many of the astrocytes were lined at the border regions of the sublayers of the molecular cell 
layer (III, Fig. 2, B2). The density of uPAR-positive astrocytes increased also in the hilus. 
Furthermore, the number and intensity of staining of uPAR-positive neurons was increased in the 
granule cell layer and hilus at 1 d post-SE compared to control animals. Substantial increase in 
neuropil staining of the dentate gyrus appeared 1 d after SE with the most remarkable increase being
observed in the inner molecular layer (III, Fig. 2, B2). Notably, very intensive neuropil labeling was 
located at the border regions between the inner and midmolecular layers, and between the mid and 
outer molecular layers. This pattern was clearer in the temporal end of the hippocampus that was more 
damaged than the septal end. Substantial neuropil staining was also found in the infragranular region of 
the hilus.
In animals sacrificed 2 days after SE, uPAR mRNA expression was 14-fold elevated as compared 
to control values (p<0.05; III, Fig. 3). At 4 days after SE, uPAR expression was still slightly elevated 
compared to controls (3-fold change) but the change did not reach statistical significance.
Immunohistochemical staining indicated that the density of darkly labeled uPAR positive glia 
continued to increase throughout the CA1 of the hippocampus (III, Table 1, Fig. 2, C3). There were 
numerous darkly labeled uPAR positive neurons in the stratum oriens (CA1) and pyramidale (III, 
CA1, Fig. 2, C3; CA3, Fig. 2, D3). As compared to the 1-day SE group, the neuropil staining increased 
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substantially throughout the CA1. The entire stratum lacunosum moleculare was also stained (see Fig. 
2, C3). The overall uPA staining in dentate gyrus at 4 d after SE resembled that observed at 1 d. 
However, in the mid and outer molecular layers, the number and staining intensity of astrocytes 
increased substantially (III, Fig. 2, A3 and B3). In addition, the staining intensity of the large neurons 
located in the granule cell layer and the hilus increased as compared to the 1 d post-SE group. 
In the 14 d epileptogenesis-group, the density of uPAR positive astrocytes decreased dramatically 
in the entire hippocampal formation as compared to that observed at the 4 day time point (III, Table 1; 
Fig. 2, B4, C4, B4). In the CA3, uPAR immunoreactivity in glia and the neuropil staining was similar 
to that encountered in controls (III, Fig. 2, D4). The intensity of uPAR labeling in the remaining 
astrocytes and neurons was also lower than that at earlier time points after SE. Further, in the 
pyramidal cell layer of the CA3a region where the large immunopositive neurons were located at 4 
days post-SE, large immunopositive granules were observed (see III, Fig. 2, D4 and Fig. 4C) that 
appeared to be located on the cellular surface and the proximal dendrites of the CA3a. The density of 
immunopositive neurons in the CA1 was low. Moderate neuropil labeling in stratum oriens and 
pyramidale of the CA1 was still present, but neuropil labeling in stratum lacunosum-moleculare was 
low. In the dentate gyrus, the intensity and number of immunopositive elements was decreased as
compared to the 1 d or 4 d groups, but was still upregulated as compared to controls. Intensely stained 
astrocytes were still present in the mid/outer molecular layer (III, Fig. 2, B4). However, the large 
immunopositive neurons observed at earlier timepoints had disappeared. Neuropil labeling was at the 
control level in all layers of the dentate gyrus. 
Intense uPAR immunoreactivity was observed in blood vessels throughout the hippocampus in 
animals that had experienced SE. The staining appeared to be located in the blood vessel endothelium 
(see III, Fig. 4D). No detailed analysis of the blood vessel expression was performed.
Expression of uPAR in epileptic rat hippocampus
No major differences we found when 14-d epileptogenesis and epilepsy groups were compared. In the 
CA1 of hippocampus proper, however, neuropil staining in the stratum radiatum was more intense in 
the 14-d epilepsy group than the epileptogenesis group. 
Cellular distribution of uPAR in the rat hippocampus
In order to confirm the cell types expressing uPAR and to study the cellular localization of uPAR 
protein in the rat hippocampus, double-immunohistochemical stainings were performed (III, Fig. 5). 
As expected, in control animals uPAR expression was detected in GFAP positive astrocytes and in 
some NeuN positive neurons. In both glia and neurons, the uPAR expression was confined mostly to 
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the cell soma part. No uPAR expression colocalized with microglial marker ILB4. Since it was 
postulated that the large uPAR-positive neurons could be interneurons, double-labeling with different 
interneuronal markers was performed. This revealed that 85% (120/142) of the large neurons that 
exhibited uPAR staining were parvalbumin interneurons. There were some layer specific differences in 
the percentage of uPAR/PARV double-labeled cells. In the pyramidal cell layer (CA3-CA1), 97% 
(73/75) of uPAR positive neurons were positive for PARV and 79% (66/84) of PARV positive cells 
were uPAR positive.  In the granule cell layer, the percentages were very similar being 96% (27/28) 
and 77% (24/32), respectively. In the hilus of the dentate gyrus, however, 51% (20/39) of uPAR 
positive neurons were PARV positive and 82% (41/50) of PARV positive cells were uPAR positive. 
Moreover, in the hilus, 33% (11/33) of uPAR positive neurons were also NPY positive and 28% 
(11/39) of NPY positive cells were uPAR positive. Finally, 38% (12/32) of hilar uPAR positive 
neurons were also SOM positive and 22% (9/41) of hilar SOM positive cells were uPAR positive. 
Only a few occasional CB and CR positive interneurons colocalized with uPAR staining.
In animals undergoing epileptogenesis, uPAR was also expressed in astrocytes and the expression 
of uPAR was intense in the astrocytic processes as well as the cell soma (III, Fig. 5, A1-A3). Similar 
to the situation in controls, no uPAR expression was found in microglial cells. uPAR was also
expressed in neurons and according to the double-staining with interneuron markers, 70% (121/173) of 
the large, darkly stained uPAR positive neurons were parvalbumin interneurons (III, Fig. 5, C1-C3). In 
the pyramidal cell layer, similar to the situation in controls, 98% (88/90) of surviving uPAR positive 
neurons were positive for PARV and 90% of PARV positive cells were uPAR positive. In the granule 
cell layer, the percentages were 92% (24/26) and 95% (21/22), respectively. In the hilus, 36% (14/39) 
of surviving uPAR positive neurons were immunoreactive for PARV and 70% (28/40) of PARV 
positive cells were uPAR positive. In the epileptogenic hilus, 43% (19/44) of uPAR positive neurons 
were NPY positive and 47% (16/34) of NPY positive cells were uPAR positive (III, Fig. 5, E1-E3). 
Finally, 33% (14/42) of hilar uPAR positive neurons were SOM positive and 26% (11/42) of hilar 
SOM positive cells were uPAR positive (III, Fig. 5, D1-D3). Similarly to control animals, only a few 
occasional calbindin and calretinin positive interneurons colocalized with uPAR staining.
5.5 Effect of uPA deficiency on neuronal damage in the hippocampus after SE (IV)
In an attempt to investigate the effect of uPA deficiency on neurodegeneration, Nissl stained mouse 
brain sections were analyzed at 6 and 20 d after intrahippocampal KA injection. Six days after KA 
injection, all mice had extensive hippocampal damage on the ipsilateral side of the hippocampus. Both 
the CA1 and CA3 principal cell layers showed more than 50% loss of neurons (IV, Table 1; Fig. 1D 
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and F). In some animals, neurodegeneration on the contralateral side was also observed (mostly CA1). 
According to semiquantitative analysis, there were no differences in the severity of neurodegeneration 
between uPA-/- and Wt mice at this time point (IV, Table 1). At 20 days after KA injection, a
progression of the neurodegeneration was observed in both genotypes. According to the 
semiquantitative analysis, neurodegeneration in the ipsilateral CA1 of Wt mice was more severe than 
that in the 6-day group (IV, Table 1, p<0.05). In the ipsilateral CA3, both in Wt and uPA-/- mice, the 
severity of neurodegeneration was comparable to that in the 6-day groups (p<0.05; see IV, Fig. 1H, J
and Table 1). Contralaterally, increased neuronal damage in uPA-/- mice was found as compared to Wt 
mice both in the CA1 (p<0.05) and in the CA3 (p<0.05, IV, see Fig. 1G and I, Table 1). Furthermore, 
in uPA-/- mice, the CA3 degeneration at 20 d was more severe than that at 6 days (p<0.01, IV, Table 
1).
Hilar cells were counted to obtain further information on the extent of neuronal damage at 20 d 
post-SE. According to the stereological counting, the number of hilar cells had dramatically decreased 
20 d after SE on the ipsilateral hilus both in Wt (p<0.005 as compared to saline-injected Wt mice, 
p<0.05 compared to contralateral side) and uPA-/- mice (p<0.005 as compared to saline-injected 
uPAK7K'.$L#<#.%$%.%'	IV, Fig. 2H). However, ipsilaterally, there was 
no difference in the hilar cell counts between Wt and uPA-/- mice. Contralaterally, the number of hilar 
cells declined in uPA-/- mice (p<0.005 as compared to saline-injected uPA-/- mice) but not in Wt mice 
(p>0.05 as compared to saline-injected Wt mice) (p<0.05; IV, see Fig. 2G).
5.6 Effect of uPA deficiency on granule cell dispersion (IV)
In order to assess the role of uPA deficiency on granule cell dispersion, a prominent feature of 
hippocampal sclerosis in human TLE, the volume of the granule cell layer was measured bilaterally in 
cresyl violet stained sections from animals sacrificed 20 days after saline (Wt n=5, uPA-/- n=5) or KA 
(Wt n=7, uPA-/- n=7) injection. In control (saline injected) Wt and uPA-/- mice, the volume of the left 
(contralateral) granule cell layer was smaller than that on the right (ipsilateral) side (p<0.05; IV, Fig. 
3). Further, the volume of the left granule cell layer in the uPA-/- mice was smaller than that in the Wt 
mice (p<0.05). In both Wt and uPA-/- mice, KA injection caused a massive enlargement of the 
ipsilateral granule cell layer. In KA injected Wt mice, the volume of the ipsilateral granule cell layer
was 4-fold greater than that in Wt controls (p<0.01). In KA injected uPA-/- mice, the volume of 
granule cell layer was enlarged 3-fold as compared to uPA-/- control mice  (p<0.01). A moderate 
increase in granule cell layer volume was found also in the contralateral side after KA injection in Wt
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and uPA-/- mice (p<0.01 for both). No difference between the KA injected Wt and uPA-/- mice was
found in the volume of the granule cell layer ipsilaterally or contralaterally.
5.7 Effect of uPA deficiency on neurogenesis (IV)
In order to elucidate the effect of uPA deficiency on neurogenesis and neuronal migration, the number 
and location of DCX-cells were investigated. According to stereological analysis, there was no 
difference in the total number of DCX-positive cells in the dentate gyrus between control Wt and uPA-
/- mice. Further, there was no statistically significant difference in the number of DCX-cells between 
control and KA-treated mice in either the Wt or the uPA-/- group at 20 d post-treatment. However, the 
number of DCX-cells was higher in KA-treated Wt as compared to uPA-/- mice (p<0.01; IV, Figs. 4C, 
E and 5A). When the septal hippocampus around the lesion area was analyzed, it was found that the 
number of DCX-positive cells had been reduced in the  KA-treated uPA-/- mice as compared to the 
KA-treated Wt mice (p<0.05) or to the saline-treated uPA-/- mice (p<0.05) (IV, Fig. 5B).
The location of the newly born cells was investigated by examining separatedly, cell numbers in 
the hilus, subgranular zone and granule cell layer. According to the stereological counting, there were 
no differences in the number of DCX-positive cells in hilus, subgranular zone or granule cell layer
between Wt and uPA mice treated with saline. KA-treatment caused an increase in the DCX-cell 
number in hilus, both in Wt and uPA-/- mice compared to saline treated animals (p<0.005 and p<0.01, 
respectively; IV, Fig. 5C and D) and no difference was found between the genotypes. No statistically 
significant change was found in the number of DCX-cells in the subgranular zone after KA-injection
as compared to saline treated mice of either genotype. However, uPA-/- mice had 36% fewer DCX-
positive cells in the subgranular zone than Wt mice after KA-treatment (p<0.01). In addition, in the 
granule cell layer the number of DCX-positive cells was 52% lower in KA-injected uPA-/- mice as 
compared to Wt mice (p<0.05).
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TABLE 3. Summary of results from the uPA and uPAR studies.
SE induced with electrical stimulation of the amygdala in rats
Animal groups control
1 d , 4 d and 14 d after SE
Study uPA expression and activity uPAR expression
Main results Expression of uPA was low in the control 
rat brain. Light uPA immunostaining
observed in astrocytes scattered around the 
hippocampus.
uPA mRNA levels increased in the rat 
temporal lobe 1 d-14 d after SE.
uPA-immunoreactivity increased 
dramatically after SE in the hippocampus. 
The peak of expression was observed 1-4 d 
after SE.
After SE, uPA expression colocalized to 
astrocytes, CA1-CA3 pyramidal neurons 
and blood vessel endothelium. uPA staining 
in hippocampal neuropil was intense in 
several areas, particularly in the inner 
molecular layer of DG.
Astrocytes expressing uPA expressed also 
radial glia marker 3CB2.
Enzymatic activity of uPA increased in the 
temporal lobe and hippocampus 1-14 d after 
SE.
Expression of uPAR was low in the control 
rat hippocampus. Light uPAR-
immunopositive staining observed in 
astrocytes and some scattered large neurons 
in the hippocampus.
uPAR mRNA levels increased at 1 d and 2 
d after SE in the rat hippocampus.
uPAR-immunoreactivity increased 
dramatically after SE in the hippocampus.
The peak of expression was observed 1-4 d 
after SE. 
After SE, uPAR expression colocalized to 
astrocytes, CA1-CA3 pyramidal neurons 
and most of the parvalbumin interneurons 
of the hippocampus. Intense neuropil 
staining was observed, particularly in the 
inner molecular layer of DG.
SE induced with i.h. KA in mice
Animal groups Wt mice: control, 6 d and 20 d after SE
uPA-/- mice: control, 6 d and 20 d after SE
Main results No differences between Wt and uPA-/- control mice in the number of hilar cells, volume of 
the GCL, and number on DCX-positive cells.
No difference between Wt and uPA-/- mice in neuronal damage at 6 d after SE. 
Neurodegeneration was significantly increased in the hilus and pyramidal cell layer in uPA-
/- mice compared to Wt mice 20 d after SE.
Number of DCX positive cells was reduced in uPA-/- mice compared to Wt mice 20 d after 
SE.
Abbreviations: DCX, doublecortin; i.h., intrahippocampal; SE, status epilepticus; uPA-/-, uPA gene deficient; 
Wt, wild type.
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6. DISCUSSION
6.1 Methodological considerations
6.1.1 Animal models
Animal models mimicking human TLE are important tools in epilepsy research. A wide range of 
animal models has been developed but none of them mimics perfectly human TLE and 
epileptogenesis. The amygdala stimulation model has been developed specifically to resemble human 
TLE in rats and has been shown to successfully mimic several aspects of human TLE such as 
epileptogenic latency phase, neuronal damage and mossy fiber sprouting in the hippocampus (Nissinen 
et al., 2000). It has been developed and is widely used in our laboratory and therefore the methodology 
was well known and tested. Further, the model does not reguire administration of chemical substances 
that could affect gene and protein expression.
In mice, the small size of animals creates limitations to the use of the models suitable for rats. 
Systemically administered KA and pilocarpine are widely used to induce SE in mice. However, strain 
differences in KA susceptibility create further limitations. Especially the C57BL6 mouse strain is 
known to be resistant to the neuronal damage evoked by systemically administered KA though the 
animals suffer severe behavioral seizures (Schauwecker et al., 2002; Mckhann et al., 2003). Therefore 
pilocarpine was used as the first choice to test the effect of genotype on SE and neuronal damage. 
However, during the course of the study it came evident that the use of pilocarpine is not feasible. If 
animals developed SE, most of them died and with lower dosages SE was not achieved. The problem 
was overcome by choosing another model, the intrahippocampal KA model. Mouse strain differences 
in KA susceptibility have not been reported for intrahippocampal administration. This model is one of
the few animal models that have been shown to mimic the GCD that is a common finding in human 
TLE (Bouilleret et al., 1999). The cellular changes as well as the development of epilepsy in this model 
are well documented (Bouilleret et al., 1999, 2000; Suzuki et al., 1995; Riban et al., 2002).
When mice are used, it should be noted that the genetic background can have a great effect on the 
results (Schauwecker, 2002; 2007). Thus, the use of appropriate control animals is crucial. In order to
avoid differences caused by genetic differences other than the lack of uPA gene, Wt animal were 
littermates from the same colony as uPA-/- mice.
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6.1.2 cDNA arrays and PCR
cDNA arrays are a powerful tool to analyze the gene expression of thousands of genes at the same 
time. However, the results depend greatly on the analysis and interpretation of data and need to be 
done with caution. The comparison of data between research groups can also be difficult because of 
differing materials and analysis procedures, especially when single genes are being studied. According 
to our preliminary unpublished data, upregulation could not be confirmed with PCR in 7 out of 15 
genes when the selection of upregulated genes was dependent on one hybridization only. Thus, the 
criteria for candidate epileptogenesis genes were set higher. The genes were considered to be up- or 
downregulated only when the expression ratio was F#<%E<
' %$'.2$'/iven 
timepoint. This change in the threshold criterion increased the number of true positive findings (3 out 
of 4). However, as this PCR data shows, some false negative/positive data is still obtained. For 
example, cystatin C did not fulfill the criterion set in this experiment but has been shown to be 
upregulated  during epileptogenesis in rat brain when this was studied with RT-PCR (Lukasiuk et al. 
unpublished) and with immunohistochemistry (Lukasiuk et al., 2002). In addition, in cDNA array uPA 
and biglycan were not considered as being upregulated in 14 d epileptogenesis group but were shown 
to be upregulated in this group with RT-PCR. In summary, though the cDNA array is an efficient way 
of screening for candidate genes other methods are needed to confirm the findings obtained with this 
technique. cDNA array is also very useful in searching for altered functional gene groups (Lukasiuk 
and Pitkänen 2004; Lukasiuk et al., 2006)
In the PCR experiments, reference genes, which are often referred to housekeeping genes, are 
frequently used to normalize mRNA levels between different samples in RT-PCR. It is important to 
choose reference/normalization genes that do not change their expression due to the treatment. There 
are a number of reference genes used in different studies, however no gene is available that can be 
appliedapplies for every situation/tissue. Thus, reference genes must be chosen according to the 
experiment and tissue under study. In the experiments 18S rRNA and GAPDH genes were used since 
these have been widely used as reference genes and shown to be stably expressed in brain tissue after 
SE and TBI (Ermolinsky et al., 2008; Rhinn et al., 2008). 
6.1.3 Specificity of immunoreactivity
Immunohistochemical stainings are complex reactions and the sensitivity and specificity of the 
antibodies are crucially important for successful staining. However, also the reaction conditions and 
tissue used can have a major impact on the staining pattern obtained (Lorincz and Nusser, 2008; Saper, 
2009). The potential problems include antigen masking (antibody cannot recognize epitope) and 
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unspecific binding of antibodies or other staining molecules (Lorincz and Nusser, 2008; Saper, 2009). 
The specificity of immunoreactivity in uPA and uPAR immunohistochemical stainings was tested first 
by omitting the primary antibody. This resulted in the disappearance of all immunostaining and thus 
confirmed that only the primary antibody was responsible for the staining. Next, the primary antibody 
(uPA and uPAR) was incubated with different concentrations of specific blocking peptide to verify that 
the antibody only attached to the tissue through the specific antigen binding site. Pre-incubation with 
the blocking peptide diminished uPA and uPAR staining in the hippocampus in a concentration
dependent manner. To further verify uPAR antibody specificity it was tested also on Wt and uPAR-/-
mouse tissue, however this antibody did not seem to work in mouse tissue. Thus, no confirmation with 
this method could be achieved. As an alternative method, it was shown that a similar staining could be
achieved with another uPAR antibody and further that this antibody recognized specifically rat uPAR 
on western blot in samples obtained from HEK 293T cells transduced with rat uPAR (III, Fig.1). Other 
antibodies used in this study have been more widely used and their specificity has been established by 
others, thus only omission of primary antibody was used to test the specificity in each of these 
stainings. The main protocols used for stainings have been tested and are widely used in the Epilepsy 
Research Laboratory.
6.2 Expression of uPA and uPAR in normal rat and mouse brain
According to this immunohistochemical analysis, the expression of uPA is low in normal rat 
hippocampus. uPA was found only in some astrocytes and in very few pyramidal neurons and blood 
vessels in the control rat hippocampus. The low protein expression was in accordance with the low 
enzyme activity measured from hippocampal samples of control rats. However, Masos and Miskin 
(1996) and Dent et al. (1993) did claim that uPA mRNA is widely expressed in granule cell layer as 
well as pyramidal neurons of the rat hippocampus. No detailed uPA protein studies in rat brain existed 
prior to the present study. These results however are in accordance with Iyer et al. (2010) indicating
that in normal adult human brain, uPA mRNA and protein levels are low. The studies suggest that uPA 
expression is mostly neuronal in normal human, rat and mouse brain (Dent et al., 1993; Masos and 
Miskin, 1996; Thornton et al., 2008; Iyer et al., 2010), however glial expression has not been studied in 
detail. Studies in cell cultures support the present finding that uPA is produced also by astrocytes 
(Rogister et al., 1988; Kalderon et al., 1990; Tranque et al., 1992, 1994; Moore et al., 2009). 
The expression of uPAR was also very low in the normal rat hippocampus and was confined to a 
small proportion of astrocytes and some individual large neurons. Double stainings confirmed that the 
large uPAR-positive neurons were mostly parvalbumin interneurons. A low expression of uPAR was 
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found also in somatostatin and neuropeptide Y positive interneurons of the hilus. Expression of uPAR 
in the normal rat brain had not been studied before this present study. Instead, there are a few reports in 
mice and humans. In agreement with the present study in rats, Cunningham et al. (2009) and Del Bigio 
et al. (1999) reported that the expression of uPAR protein was low in normal mouse hippocampus and 
confined to small population of neurons. Gveric et al., 2001 stated that in normal adult human brain 
uPAR was undetectable. In contrast, Beschorner et al. (2000) observed that uPAR could be found in 
epithelial cells of the choroid plexus, endothelial cells, and arachnoid cells in the human brain. The 
recent study of Iyer et al. (2010) indicated that uPAR mRNA and protein levels were low in the normal 
human hippocampus. In accordance with the present finding of astrocytic expression of uPAR, 
astrocytes cultured for 5 days in vitro obtained from P1 mice have been shown to express uPAR (Del 
Bigio et al., 1999). Fetal human astrocytes grown in vitro also express uPAR (Le et al., 2003). 
Cunningham et al (2009) described low expression of uPAR protein in microglial cells in mouse brain, 
however, in this study uPAR expression was not observed in rat microglia. In summary, previous 
studies together with the results of this dissertation indicate that uPA and uPAR are expressed at low 
levels in mature neurons and glia both in rodent and human brain.
6.3 Increased expression and activity of uPA after SE
According to these results, the expression of uPA mRNA and protein in the rat brain had increased 
already 1 d after SE and they remained elevated for up to two weeks. Further, the enzymatic activity of 
uPA was elevated in the hippocampus and temporal lobe up to 14 days after SE. These findings are in 
accordance with the gene-expression study of Gorter et al. (2007) showing increased uPA mRNA 
expression in rat brain 1-7 days after SE induced with hippocampal stimulation. Masos and Miskin 
(1997) described an increase in uPA mRNA in mouse brain 1-4 days after KA-induced SE. Further, the 
neurotoxicant, TMT has also been shown to increase uPA mRNA expression in the rat hippocampus 
and frontal lobe followed by increased enzymatic activity (Dencoff et al., 1997). In addition, ischemia 
(Cinelli et al., 2001; Sironi et al., 2003; Adhami et al., 2008) and TBI (Rall et al., 2003) have been 
shown to increase uPA expression and/or activity in the brain. Very recent data from human TLE 
specimens described increased uPA mRNA and protein expression in hippocampal samples with 
sclerosis (Iyer et al., 2010). Taken together, the current evidence indicates that several brain insults 
trigger upregulation of uPA and suggest that uPA is involved post-injury processes common for these 
brain insults.
Since the cellular distribution of uPA, was also evaluated, it was found that the most profound 
expression of uPA in the rat hippocampus was localized to astrocytes and pyramidal neurons. This is 
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consistent with recent findings in human TLE samples (Iyer et al., 2010). According to Kalderon et al. 
(1990), the expression of uPA and tPA in rat astrocytes is developmentally regulated so that immature 
astrocytes express both plasminogen activators but mature astrocytes express only tPA. Further, uPA 
expression is induced in vitro by agents that trigger astrocyte proliferation, e.g. fibroblast growth factor 
(Rogister et al., 1988), epidermal growth factor (Tranque et al., 1994) and phorbol ester (Tranque et 
al., 1992).On the other hand, treatment with uPA has been reported to induce astrocyte proliferation 
(Moonen et al., 1985). The present data provide the first evidence that astrocytic expression of uPA 
protein can be triggered by epileptogenic brain insults in vivo. Further, uPA expression in astrocytes 
after SE might be involved in the proliferation of astrocytes which is a common finding in human TLE.
Interestingly, most of the uPA-expressing astrocytes were oriented perpendicular to the principal 
cell layer in the hippocampus and expressed the radial glial marker 3CB2. In the normal situation, 
radial glia are present only during brain development and they facilitate and act as guides for neuronal 
migration (Edwards et al., 1990). Some studies have proposed that radial glia within the granule cell 
layer might be facilitating GCD in epileptic hippocampus (Crespel et al., 2002). However, no 
uPA+3CB2 positive astrocytes were observed within the granule cell layer i.e. it is unlikely that these 
astrocytes facilitate granule cell migration by forming a migratory scaffold. However, some kind of 
other facilitatory function on cell migration cannot be ruled out. Expression of radial glia marker in 
these astrocytes might indicate that these astrocytesregain some of their immature properties after SE. 
This is consistent with previous theories suggesting reactivation of developmental processes during 
epileptogenesis (Elliott et al., 2003; Elliott and Lowenstein, 2004). The expression of uPA in astrocytes 
that were lined between the inner and mid molecular layer indicate that these astrocytes could well
facilitate MFS, a commonly observed trait in human and experimental epilepsy (Sutula et al., 1989; 
Pitkänen et al., 2000). In MFS, the axons of granule cells sprout into the inner molecular layer and 
make connections to the apical dendrites of the granule cells. uPA expressed by astrocytes in this 
region could facilitate the penetration of growing axons by ECM proteolysis or evoke activation of 
growth factors to promote axon regeneration. In fact, mature astrocytes transfected with uPA have 
been demonstrated to support increased axonal growth of dorsal root ganglion neurons (Muir et al., 
1998). Furthermore, tPA has been shown to regulate MFS in mice after SE (Wu et al., 2000). Whether
this is true also for uPA, needs further studies.
In addition to astrocytes, uPA was also expressed in the pyramidal neurons in the CA1 and CA3 
subfields of the hippocampus after SE. This is consistent with previous studies in mice showing 
increased uPA mRNA expression in neurons in the CA1 and CA3 pyramidal cell layer, stratum oriens, 
and the hilus of the dentate gyrus after KA-induced SE (Masos and Miskin, 1997). Further analysis 
revealed that the expression had occurred in areas where there was neuronal damage. Interestingly, 
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neurons are known to express uPA also in the sclerotic hippocampus of TLE patients (Iyer et al., 2010) 
but in detail knowledge about the role of uPA in neurodegeneration is lacking. The possible 
degenerative properties of uPA include activation of ECM proteolysis which kills neurons (Chen and
Strickland, 1997; Indyk et al., 2003) or disruption of the BBB leading to inflammation and edema
(Rosenberg et al., 1994, 1996; Kataoka et al., 2000). However, uPA could also promote pro-recovery 
related proteolysis and activation of growth factors. In addition, in cancer cells, uPA and uPAR have 
anti-apoptotic effects (Alfano et al., 2005; Pulukuri et al., 2005).
An increase in uPA-expressing blood vessels was also found after SE. In agreement, human TLE 
samples with hippocampal sclerosis have shown persistent upregulation of uPA in hippocampal blood 
vessels (Iyer et al., 2010). The localization of uPA in blood vessels was confirmed by double labeling
with EBA antibody. EBA is expressed in the endothelial cells of cerebral microvessels with an intact 
blood–brain barrier, and the loss of EBA immunoreactivity is considered as an indicator of disruption 
of the normal structure of the vessel wall (Sternberger and Sternberger, 1987; Nishigaya et al., 2000). 
Interestingly, even though uPA and EBA seemed to be expressed in the same blood vessels, in most 
cases, uPA expression did not co-localize with EBA-positive cells. In addition, some structures, 
presumed to be blood vessels according to their morphology, expressed only uPA after SE. Thus, uPA 
was expressed in blood vessel endothelium that according to EBA staining had lost the integrity of the 
BBB. There are some reports that uPA can facilitate BBB damage in ischemic and brain stab wound 
injury models due to breakdown of the microvascular ECM (Rosenberg et al., 1994; 1996; Kataoka et 
al., 2000). Expression of uPA in blood vessels could also be linked to angiogenesis since quiescent 
endothelium does not express uPA but exposure of endothelial cells to angiogenic growth factors
upregulates uPA expression in endothelial cells (Pepper et al., 2003). Further, there are several reports 
that uPA and uPAR are expressed during angiogenesis (reviewed by Pepper et al., 2001) and uPA
expression has been shown to enhance the invasive capacity of endothelial cells (Gualandris et al., 
1997; Parfyonova et al., 2002). Recent evidence indicates that angiogenesis is one of the 
reorganization processes occurring during human TLE (Rigau et al., 2007). Further, in animal models, 
it has been demonstrated that electroconvulsive seizures can induce proliferation of endothelial cells 
(Hellsten et al., 2004) and increase angiogenesis in the rat hippocampus (Newton et al., 2006, Hellsten 
et al., 2005). Angiogenesis is accompanied by an increased expression of vascular endothelial growth 
factor (VEGF) (Croll et al., 2004; Nicoletti et al., 2008) and the interaction between VEGF with its 
receptor VEGFR-2 induces rapid pro-uPA activation on the surface of the endothelial cells (Prager et 
al., 2004a). The two mechanisms by which the uPA and plasmin are believed to contribute to 
angiogenesis are 1) the degradation of ECM and 2) the activation of growth factors (Parfyonova et al., 
2002).
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There was also a marked increase in neuropil staining at 1–4 days after SE in all subfields of the 
hippocampus except in the stratum lucidum of CA3. This staining may represent uPA released from 
cells into the extracellular space. Previous in vitro studies have demonstrated a rapid release of uPA 
from the cell after its synthesis (Pittman et al., 1989). Whether neuropil labeling reflects uPA release 
from neurons or glia in vivo remains to be explored.
6.4 Increased expression of uPAR after SE
As the uPA activity is regulated by its receptor uPAR and the receptor is also needed for the initiation 
of intracellular signaling, it was decided to study also the expression of uPAR during epileptogenesis 
and epilepsy. Further, uPAR is known to be involved in several reorganization events in normal tissues 
as well as cancer tissue suggesting a role for uPAR also in pathologic plasticity of the brain tissue. 
There was upregulated expression of uPAR mRNA 1-2 d after SE and this correlated nicely with
immunohistochemical staining showing substantial increase in uPAR immunoreactivity in neurons,
astrocytes and the neuropil 1-4 d after SE. It seems that there are no other studies of uPAR expression
in traumatized rat brain. However, this present finding is in accordance with the recent study of 
Cunningham et al. (2009) showing increased uPAR mRNA and protein expression in the mouse 
hippocampus after intrahippocampal lipopolysaccharide (LPS) or KA injection. Further, studies of 
human autopsy tissue have revealed a transient upregulation (peaking 3–4 days after trauma) of uPAR 
protein expression following TBI and focal cerebral infarction (Beschorner et al., 2000). In addition, in 
human hippocampal sclerosis samples, uPAR mRNA and protein expression is upregulated (Iyer et al., 
2010). Taken together, it appears that uPAR expression is induced by several brain insults in human, 
rat and mouse brain. 
After SE, the most profound expression of uPAR was detected in rat astrocytes but upregulated 
uPAR expression was also found in neurons, neuropil and blood vessels. In frontal cortex of human 
frontal lobe epilepsy patients, increased uPAR expression has been found in neurons and astrocytes but 
also in microglia (Liu et al., 2010). In traumatized human brain, uPAR expression has been localized to 
astrocytes, the endothelial cells of blood vessels, invading granulocytes, and activated 
microglia/macrophages (Beschorner et al., 2000). In traumatized mouse brain uPAR is expressed 
mostly in cells with microglial morphology but also in the neuropil (Cunningham et al., 2009). In 
samples from patients with AD or MS, the increased expression of uPAR is located in microglia 
(Washington et al., 1996; Walker et al., 2002). Expression of uPAR has also been demonstrated in 
cultured human microglia obtained from adults being operated due to drug-refractory epilepsy;
however no uPAR mRNA or protein expression was detected when microglia was studied immediately 
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ex vivo (Washington et al., 1996). In accordance, uPAR expression was not observed in microglial 
cells after SE in the rat brain. Whether the differences in findings of microglial uPAR expression 
relates to antibodies or staining protocols used or actual differences in uPAR expression in different 
brain pathologies remains to be investigated. 
Increased uPAR expression was observed in hippocampal neurons after SE. This is in line with 
previous studies showing increased neuronal expression of uPAR in trauma models in rodents as well 
as in human neurodegenerative diseases. For example, Hayden and Seeds (1996) found increased 
uPAR mRNA expression in dissociated cultured postnatal (P2) dorsal root ganglion neurons during 
axonal regeneration. In a mouse model of sciatic nerve crush, uPAR mRNA expression remained
upregulated for up to 7 days post-injury in the dorsal root ganglion neurons (Siconolfi and Seeds, 
2001b). In the human brain, upregulated uPAR protein expression has been found in cortical neurons 
of patients with Creutzfeldt-Jacob’s disease and AD (Deininger et al., 2002). These data suggest that 
various types of neurodegenerative processes can trigger expression of uPAR. 
Interestingly, the parvalbumin interneurons were the neuronal subpopulation showing the most 
striking increase in uPAR expression after SE. In the hilus of the dentate gyrus, uPAR expression was 
also located in some NPY and somatostatin positive interneurons. It has been reported that uPAR is 
highly expressed in neurons in the developing mouse brain (Del Bigio et al., 1999) and uPAR has been 
shown to be important for interneuron development in mice (Powell et al., 2003; Eagleson et al., 2005; 
Levitt, 2005). uPAR-/- mice show substantial decrease in the number of GABAergic neurons in the 
parietal cortex, which is caused both by a drastic reduction in the number of parvalbumin cells and a
decrease in GABA immunoreactivity in the parvalbumin, calretinin, and somatostatin positive
interneurons. In contrast, in the hippocampus of uPAR-/- mice, the number of somatostatin
immunoreactive neurons is decreased (Powell et al., 2003; Eagleson et al., 2005). These changes result 
in increased anxiety, diminished social interaction, increased susceptibility for pentylenetetrazole-
induced seizures and also in the occurrence of spontaneous seizures (Powell et al., 2003; Levitt, 2005).
However, the role of uPAR in the adult brain is still not clear. Different subtypes of interneurons show 
different susceptibilities to neuronal death after SE. A decrease in the number of parvalbumin, NPY, 
and somatostatin positive neurons has been described in experimental and human epileptic 
hippocampus (Arellano et al., 2004; Mathern et al., 1995; Sloviter et al., 2003). Thus, uPAR might 
have a role in neuronal survival. A study with uPAR-/- mice did indicate that uPAR has 
neurodegenerative properties after brain ischemia (Nagai et al., 2008). In addition to the modulation of 
neuronal survival, uPAR could also be modulating/facilitating formation of new synaptic connections 
on the surviving cells as these events also require proteolysis (Madani et al., 2003). A large proportion 
of mossy cells that provide excitatory input to interneurons are also lost and leave vacant synaptic sites 
71
on the surface of these neurons (Blümcke et al., 2000; Sloviter et al., 2003). Interestingly, uPAR 
staining in neuropil and astrocytes was intense also in the inner molecular layer where granule cells 
sprout their axons in epileptic human and rat brain (MFS). The ECM has been shown to have a major 
role in synaptic organization (Dityatev and Schachner, 2006). These findings and the present 
observation that uPAR is expressed in the same regions as uPA indicate that uPAR could function by 
facilitating activation of uPA and subsequent activation of proteolysis or/and latent growth factors 
needed for reorganization of synaptic contacts and growth of axons through the ECM. uPAR may also 
have uPA independent regulatory roles, as uPAR is known to cluster with several cell surface proteins 
(Blasi and Carmeliet, 2002). Whether uPAR has a role in neuronal survival and/or formation of new 
neuronal connections during epileptogenesis at present is only speculation and needs further 
investigations. 
Similarly to uPA, the expression of uPAR was increased in hippocampal blood vessels after SE. 
This could indicate uPAR involvement in angiogenesis recently shown to be one of the reorganization 
events that occur in the brain during epileptogenesis. Angiogenesis has been shown to occur after TBI, 
stroke and SE as well as in the epileptic human hippocampus (Tang et al., 2007; Morgan et al., 2007; 
Rigau et al., 2007). Further, the expression of the angiogenic factor, VEGF, increases after 
epileptogenic insults (Croll et al., 2004; Rigau et al., 2007; Nicoletti et al., 2008) and VEGF increases 
uPA and uPAR expression in endothelial cells (Mandriota et al., 1995; Gualandris et al., 1997; Prager 
et al., 2004b). The importance of the uPA-uPAR interaction during angiogenesis has been 
demonstrated in a number of in vivo systems (Pepper et al., 2001). It is possible that uPAR may be 
able to facilitate angiogenesis through activation of proteolytic activity that has two possible functions, 
degradation of ECM and activation of angiogenic growth factors. uPAR could also initiate the 
intracellular signaling that ultimately promotes endothelial cell proliferation.
6.5 Effect of uPA deficiency on reorganization of neuronal tissue during epileptogenesis
6.5.1 Neurodegeneration
Neuronal death is a major consequence of SE in humans and animal models (Pitkänen and Sutula, 
2002; Coulter and DeLorenzo, 1999). Masos and Miskin (1997) noted that uPA mRNA was
upregulated in mouse brain 1-4 days after i.h. KA injection. The most profound upregulation of uPA 
protein expression and activity of uPA in the rat brain was detected 1-4 days after SE in areas of major 
neurodegeneration. However, according to the present findings, uPA deficiency in mice does not have 
an effect on the neuronal cell death in the hippocampus observed at 6 days after i.h. KA induced SE. 
This confirms the observations of Tsirka et al. (1997) who did not find difference in hippocampal 
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neurodegeneration in uPA-/- and Wt mice 5 days after i.h. KA injection (only 2 uPA-/- mice studied). 
The present results are also in accordance with ischemia studies indicating that the infarct size in uPA-
/- mice is comparable to that in Wt mice at 24 h after focal cerebral ischemia (Nagai et al., 1999b).
Further, no significant correlation has been found between increased uPA expression/activity and acute 
neuronal damage evoked by ischemia (Hosomi et al., 2001). Thus, according to the present data, 
although uPA is rapidly induced after epileptogenic insults, uPA does not seem to have an effect on 
acute post-injury neurodegeneration.
Neurodegeneration may continue up to 2 months after SE (Pitkänen and Sutula, 2002) and 
significant neurodegeneration in the dentate hilus, and the CA1 and CA3c sub regions is a common 
finding in TLE patients (Mathern., et al., 1997). It was shown that uPA was still upregulated 14 d after 
SE in the rat brain. Thus, it was decided to test whether uPA has a role in the progression of 
neurodegeneration. At 20 days post-SE, neurodegeneration had drastically progressed from that 
observed at 6 days in the contralateral hippocampus of uPA-/- mice but not in Wt mice. Stereological 
counting also revealed that 45% of hilar cells were lost contralaterally in uPA-/- mice while the cell 
number in Wt mice remained relatively normal. Since there was no difference in the severity of SE 
between genotypes and no difference in neurodegeneration acutely after SE, the progressive 
neurodegeneration was caused by deficiency of uPA not differences in SE. This data is in accordance 
with Morales et al. (2006) showing larger cortical damage in uPA-/- mice 2 weeks after TBI. Thus, in 
both brain insults, uPA is neuroprotective and seems to contribute to the recovery process. This result 
is supported by findings in other tissues. A study of Siconolfi and Seeds (2001a) reported that uPA is 
important in the recovery of hindlimb function in a mouse model of sciatic nerve crush. Further, Lluis 
et al. (2001) and Sisson et al. (2009) have shown that uPA-/- mice exhibit retarded muscle regeneration 
after damage featured by decreased proliferation of myoblasts and regeneration of muscle fibers. 
Taken together, the current data indicates that uPA has a pro-recovery function in several tissues 
including brain.
It is interesting that uPA deficiency caused increased neurodegeneration as one would have 
predicted the opposite result according to current knowledge. It has been previously speculated that 
increased uPA expression and activity in rat brain could contribute to neurodegeneration by 
interrupting cell–cell and cell–matrix interactions (Chen and Strickland, 1997) and by disrupting the 
blood–brain barrier leading to edema and amplification of the inflammatory reaction (Rosenberg et al., 
1994, 1996; Kataoka et al., 2000). Further, according to Thornton et al (2008), constitutively active 
uPA at the neuronal membrane may contribute to IL-'&.&%%2'.'3'&%-astrocyte co-
cultures by activating pro-MMP9. In cancer cells, however, uPA and uPAR possess anti-apoptotic 
effects (Alfano et al., 2005; Pulukuri et al., 2005). There are several possible mechanisms that might 
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underlie the neuroprotective effects of uPA. Moonen et al. (1985) have noted that uPA can trigger glial 
proliferation and this may be needed for the recovery of neural tissue and protection of remaining 
neurons. Further, proteolytic activity of uPA and consequent activation of plasminogen system and 
several MMPs can facilitate the clearance of dying cells and the reorganization of the ECM which 
facilitates survival of neurons (Lo et al., 2002). It has been claimed that uPA can also facilitate 
activation of growth factors or initiate intracellular signaling through uPAR (Blasi and Carmeliet, 
2002), and those properties may be crucial for the survival of remaining neurons.
6.5.2 Granule cell dispersion
Granule cell dispersion is a common finding (found in 40% of operated patients) in human temporal 
lobe epilepsy (Houser, 1990a). Animal models of epilepsy have indicated that GCD is a consequence 
of enhanced neurogenesis (Parent et al., 1996, 1997; Jessberger et al., 2005; Gong et al., 2007) or a 
displacement of the adult mature granule cells (Nitta et al., 2008; Heinrich et al., 2006). In both cases,
uPA could facilitate cell movement by causing proteolysis of the ECM and detachment of cells from 
their matrix. During nervous system development in the mouse, uPA expression has been shown to 
coincide with neural crest cell migration (Menoud et al., 1989). Further, in cancer tissue, increased 
expression of uPA-uPAR can facilitate the spread of the cancer cells (Andreasen et al., 2000). 
Increased uPA expression was detected in astrocytes and neuropil of the DG molecular cell layer in rat 
brain after SE. In mouse brain, uPA mRNA has been shown to be expressed in hilus and molecular 
layer of DG after KA-induced SE (Masos and Miskin, 1997). Further, granule cells in human TLE 
samples with hippocampal sclerosis display a prominent expression of uPA (Iyer et al., 2010).
In an attempt to assess the role of uPA in granule cell migration, the volume of granule cell layer 
was measured both in control and KA injected mice of both genotypes. When analyzing the volume of 
the granule cell layer in control mice, it was found that the granule cell layer was about 15% larger on 
the right as compared to the left side in both mouse genotypes. This is in agreement with previous 
observations by Tabibnia et al. (1999) who reported asymmetry in the volume of the granule cell layer 
in mice with C57BL6J background. Interestingly, it was also found that the volume of the left granule 
cell layer in uPA-/- mice was significantly smaller than that in Wt mice. This is the first report of a 
phenotypic change in the brain of the uPA-/- mouse.
In accordance with previous studies (Suzuki et al., 1995; Bouilleret et al., 1999; Riban et al., 2002), 
mice injected with KA had extensive granule cell dispersion ipsilaterally 20 days post-SE. However, 
there was no difference between uPA-/- and Wt mice. In addition on the contralateral side, both uPA-/-
and Wt mice displayed an increased granule cell layer volume as compared to saline-injected mice 
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with no difference between the genotypes. In summary, although uPA facilitates cell migration in 
several tissues it does not seem to have a role in the GCD in mouse. However, this present data does 
not clarify whether uPA deficiency can affect the rate of GCD development. In addition, as 
interspecies variation in uPA expression has been documented (Masos and Miskin, 1996, 1997), it 
cannot be ruled out that uPA has a role in GCD in some other species. Recently it was shown that 
granule cells in human HS specimens express uPA (Iyer et al., 2010), but its role remains to be 
explored.
6.5.3 Neurogenesis
There are several animal studies demonstrating that seizures and SE increase neurogenesis (Parent et 
al., 1997, 2006; Bengtson et al., 1997; Scharfman and Gray, 2007). However, in rats neurogenesis 
returns to the baseline by about 2 months after SE (Jessberger et al., 2007) and is decreased by 5 
months after SE (Hattiangady et al., 2004). Similarly, neurogenesis is decreased in the dentate gyrus of 
TLE patients who suffer frequent seizures (Pirttilä et al., 2005). Mouse brain sections were stained 
with DCX-antibody, to study the effect of uPA-/- deficiency on neurogenesis. DCX is a microtubule 
binding protein expressed almost exclusively in immature neurons (Couillard-Despres et al., 2005). 
The expression of DCX starts as neuroblasts are generated, peaks during the second week, and is 
downregulated when neurons start to express the mature neuronal markers (Cooper-Kuhn and Kuhn, 
2002; Rao and Shetty, 2004). 
In control mice, no differences were found between Wt and uPA-/- mice in the number of DCX-
positive cells, suggesting that uPA deficiency does not affect the basal rate of neurogenesis. At 20 days 
after SE, the number of newly-born cells had increased by 18% (although not significantly) in Wt mice 
but remained unchanged in uPA-/- mice. Thus, the number of DCX cells was significantly lower in 
uPA-/- mice than Wt mice. According to previous studies, the decrease in neurogenesis is linked to the 
severity of hippocampal damage in rats (Hattiangady et al., 2004; Heinrich et al., 2006) and humans 
(Mikkonen et al., 1998). Thus, the lack of neurogenesis in uPA-/- mice could have resulted from the 
larger damage observed in the hippocampus of these mice. However, there was no correlation between
the number of hilar and DCX-positive cells in either genotype. Thus, hilar damage is unlikely to
explain the difference in the number of newly-born cells between the genotypes. Further, there were no 
differences between Wt and uPA-/- mice in the development of epilepsy and seizure number or
frequency after KA, thus these factors cannot account for the difference in neurogenesis between the 
genotypes. These data suggest that uPA has a role in the roliferation of neuronal precursors. The 
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possible mechanisms could involve activation on growth factors by uPA or intracellular signaling
through uPAR.
6.6 Future directions
It was demonstrated that uPA and uPAR are both induced by SE and expressed in the same cell types. 
Further, uPA has a favorable role in neuronal survival and neurogenesis after SE. Whether the action 
of uPA is mediated via uPAR mediated cell signaling needs further confirmation. 
Immunohistochemical techniques could be employed to study the colocalization of uPA and uPAR in 
the brain tissue after SE. Cell cultures could also be used to study the function of uPA-uPAR system 
after excitotoxic damage. Further, information on uPA-uPAR function could be obtained by 
conducting a similar KA study in uPAR deficient mice as was performed for uPA mice. Studies in 
knockout mice and ischemic stroke have indicated that uPA and uPAR possess independent functions 
since uPAR-/- and uPA-/- mice exhibit different degrees of acute damage after infarction (Nagai et al., 
2008). Whether this is the case after SE, needs to be clarified. However, interpretation of knockout 
data can be difficult, e.g. uPAR-/- mice have been shown to have spontaneous seizures and 
disturbances in interneuron development (Powell et al., 2003; Eagleson et al., 2005; Levitt et al., 
2005), which could affect the findings. The an alternative option would be to block or modify uPA-
uPAR interaction in the adult animal, preferably with a technique that can be used in both mice and 
rats. Cancer research has provided some possible tools that could be employed for this task, e.g.
transduction of expression vectors for inhibitory molecules or small interfering RNA molecules 
(siRNA) for uPA/uPAR.
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7. CONCLUSIONS
This study started with a very general question about the gene-expression changes during 
epileptogenesis and epilepsy. One of the most upregulated genes found in the array study was uPA and 
it was selected for further investigation. Thus, the principal aim of this study has been to elucidate the 
expression, activity and function of uPA and its receptor uPAR during epileptogenesis. The main 
findings can be summarized as follows:
I) A total of 282 genes were found with altered expression during epileptogenesis and epilepsy in the 
hippocampus and extrahippocampal temporal lobe. The temporal changes of gene-expression during
epileptogenesis were profiled and uPA was found to be one of the highly upregulated epileptogenesis-
related genes found.
II) The expression of uPA and its receptor uPAR was low in the normal rat hippocampus. The 
expression of uPA and uPAR confined to a small group of astrocytes and CA1-CA3 pyramidal
neurons. uPAR was expressed also in some occasional large parvalbumin interneurons.
III) The expression of uPA and uPAR increased dramatically after SE in the rat hippocampus, followed 
by increased uPA activity. The uPA and uPAR protein expression peaked 1 and 4 days after SE but 
had returned close to the control level by day 14, though at this time uPA activity was still upregulated. 
In the epileptogenic rat hippocampus, uPA was expressed by astrocytes, pyramidal neurons and blood 
vessels. uPAR was expressed in blood vessels, astrocytes, pyramidal neurons and parvalbumin 
interneurons throughout the hippocampus and in some neuropeptide Y and somatostatin interneurons 
in the hilus.  
IV) It was found that uPA deficiency did not affect acute neurodegeneration (6 d) after SE induced by
i.h. KA but significantly enhanced hippocampal neurodegeneration at 20 days after SE. 
V) In mice, uPA deficiency evoked a decrease in the dentate gyrus neurogenesis after SE. The number 
of new neurons did not correlate with the extent of the damage, suggesting that other factors had 
contributed to the decrease in neurogenesis in uPA-/- mice. 
VI) No effect of uPA deficiency was observed on GCD 20 d after SE in mice.
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In summary, the present data show that uPA as well as its receptor uPAR are induced by SE and that 
uPA has a role in epileptogenic reorganization of the hippocampus. These results indicate that uPA is 
involved in post-acute neuronal death and neurogenesis in mice but does not participate in GCD.
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The cellular reorganization of the 
brain tissue during epileptogenesis 
has been widely characterized, 
however, the molecular alterations 
evoking these changes are poorly 
understood. The aim of this study 
was to characterize the gene-
expression changes that occur during 
epileptogenesis and to study the 
function of one of the genes in detail. 
Expression and activity of uPA and 
its receptor uPAR was investigated 
in the normal rat brain and during 
epileptogenesis and the role of uPA in 
neurodegeneration, neurogenesis and 
granule cell dispersion was assessed 
using uPA knockout mice.
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